



X=Y–ZH compounds as potential 1,3-dipoles. Part 64: Synthesis of highly substituted conformationally restricted and spiro nitropyrrolidines via Ag(I) catalysed azomethine ylide cycloadditions[☆]

Ronald Grigg^{*}, Colin Kilner, Mohammed A.B. Sarker, Cecilia Orgaz de la Cierva, H. Ali Dondas

Molecular Innovation, Diversity and Automated Synthesis (MIDAS) Centre, School of Chemistry, Leeds University, Leeds LS2 9JT, UK

ARTICLE INFO

Article history:

Received 26 March 2008

Received in revised form 10 May 2008

Accepted 30 May 2008

Available online 5 June 2008

Keywords:

Metallo-azomethine ylides

Cycloaddition

Silver oxide

Nitroolefins

Pyrrolidines

Spirocycles

ABSTRACT


1,3-Dipolar reactions of imines of both acyclic and cyclic α -amino esters with a range of nitroolefins using a combination of AgOAc or Ag₂O with NEt₃ are described. In most cases the reactions were highly regio- and stereospecific and *endo*-cycloadducts were obtained in good yield. However, in a few cases the initially formed cycloadducts underwent base catalysed epimerisation. The stereochemistry of the cycloadducts was assigned from NOE data and established unequivocally in several cases by X-ray crystallography.

© 2008 Elsevier Ltd. All rights reserved.

1. Introduction

We introduced facile and wide ranging metal salt–tertiary amine catalysed cycloaddition reactions of imines, activated by an appropriately located carbanion stabilising substituent, with electron deficient alkenes.¹ Subsequently, we have utilised this methodology for the synthesis of a wide variety of heterocycles including pyrrolidines, indolizidines² and spiro nitrogen heterocycles³ as well as the synthesis of pyrrolidine based β -lactams,⁴ epibatidine analogues^{5a} and uracil polyoxin C analogues.^{5b}

Dopamine **1** is one of the most important neurotransmitters, the body's natural stimulants, and plays a key role in schizophrenia and Parkinson's disease. Several reports appear in the literature for the synthesis of both simple and conformationally restricted dopamine analogues⁶ and evaluation of their biological properties. Nitropyrrolidines are potentially useful as sources of conformationally restricted analogues of dopamine **1** and DOPA **2**⁷ (vide infra). These type of compounds, e.g., **3–5** are accessible via 1,3-dipolar cycloaddition of appropriate azomethine ylides and nitrostyrenes. Nyerges et al.⁸ applied this cycloaddition methodology to the stereoselective synthesis of aza-cephalotaxine^{8a,b} and indolic



[☆] See Ref. 3b.

^{*} Corresponding author. Tel.: +44 (0) 113 3436501; fax: +44 (0) 113 3436501.

E-mail address: r.grigg@chem.leeds.ac.uk (R. Grigg).

aza-analogues^{8c} of cephalotaxine. They have also reported a new method for the synthesis of substituted pyrroles^{8d} from nitropyrrolidines. Several authors explored the 1,3-dipolar cycloaddition of both non-stabilised⁹ and stabilised¹⁰ azomethine ylides with nitroolefins for the synthesis of substituted nitropyrrolidines. For stabilised azomethine ylides it was concluded that lithio-azomethine ylides¹⁰ undergo preferential formation of *endo*-cycloadducts whilst silver salts favour the formation of *exo*-cycloadducts. Further work showed that incorporating certain groups in the aromatic moiety of aryl azomethine ylides modifies the stereoselectivity.^{10b} These latter results confirmed prior work by our group on

proton-sponge effects in azomethine ylide formation.¹¹ An asymmetric catalytic version of 1,3-dipolar cycloaddition of nitroalkenes to an imino ester derived from glycine has been reported¹² as has microwave assisted synthesis of highly substituted nitroproline esters via 1,3-dipolar cycloaddition.¹³

2. Results and discussion

This paper describes our studies of the silver catalysed synthesis of nitroproline derivatives **3** and their derivatives **4** and **5** all of which proceed via *endo*-transition states. The latter provide interesting dopamine mimetics because of the conformational rigidity conferred by the five-membered ring and the differing dihedral angle between the aryl and amine moieties. We further report a series of spirocyclic nitroproline derivatives arising from homoserine lactone **11**.

3. Cycloadditions of non-cyclic imines **6a–f**

A number of nitroolefins **7a–f** were examined to explore the diversification of the metallo-azomethine ylide cycloaddition. These were prepared from the corresponding aryl aldehydes by the Henry reaction¹⁴ and were reacted with a series of aryl or aliphatic imines of cyclic or acyclic α -amino esters.

The aryl imines **6a–f** underwent cycloaddition reactions with nitroolefins in toluene in the presence of NEt₃ and Ag₂O (10 mol %) or AgOAc (1.5 mol equiv) (Scheme 1). The results of the reactions are presented in Table 1. The cycloaddition of the less hindered imines **6a,d** with anthracene nitrostyrene **7a** afforded single cycloadducts *endo*-**9a,b** in good yield (72–80%) (Table 1, entries 1 and 2), whereas imines **6b,c** from alanine and phenylalanine failed to react under the same conditions due to the steric hindrance between the Me and Bn groups of the imines and the anthracenyl group of the dipolarophile.


Similar cycloaddition of imines **6b,c,e,f** with indolyl nitrostyrene **7b** afforded single cycloadducts **9d,e,g,h** (Table 1, entries 4, 5, 7 and 8), whereas glycine imines **6a,d** afforded a 3–5:1 mixture of *endo*-**9c,f** and *exo*-**10c,f** cycloadducts (Table 1, entries 3 and 6), respectively. Töke et al.¹⁰ have observed similar results in the 1,3-dipolar

cycloaddition of glycine imine with different nitroolefins and they have reported that silver salts favour the formation of *exo*-cycloadduct in the case of nitroolefins with bicyclic aryl groups. They have suggested that secondary orbital interactions of the aryl groups play a major role in this change of stereoselectivity. This type of interaction is not possible in the case of imines **6** (R=Me or Bn) because of the steric hindrance between the bulkier groups (Me and Bn) of the imines and the aryl group of the nitroolefins. Therefore, in all cases the cycloaddition reactions were overwhelmingly *endo*-specific.

Similarly, cycloaddition of imines **6b–e** with nitroolefins **7c–f** afforded *endo*-cycloadducts **9j–p,r–u** (Table 1, entries 10–16 and 18–21) whereas glycine imine **6a** with nitroolefins **7c,e** afforded a 2–3:1 mixture of *endo*-**9i,q** and *exo*-**10i,q** cycloadducts (Table 1, entries 9 and 17), respectively. Nitroolefin **7f** reacted with alanine imine **6b** to give a 3:1 mixture of *endo*-**9v** and *exo*-**10v** cycloadducts (Table 1, entry 22).

Product structures indicate that in all cases the imines generate the expected metallo-1,3-dipoles **8a–f** stereoselectively under kinetic control and the coordination of the metal ion depicted in **8** is believed to be responsible for this kinetic preference.¹⁵ The potential cycloadducts **9** and **10** arise from the dipoles **8** via *endo*- and *exo*-transition states, respectively. Structural assignments are based on ¹H COSY and NOE data. For example, the methoxy signal at 3.86 ppm in **9f** indicated a *trans* disposition of the ester and the indolyl groups, whilst in **10f** the methoxy signal occurs at 3.06 ppm suggesting shielding of the OMe by a *cis*-indolyl group. This observation was confirmed (Fig. 1) by NOE experiments. Thus the irradiation of H-4 in **9f** effects a 9.1% enhancement of the signal for H-5 suggesting *cis* relationship between H-4 and H-5, whereas a smaller enhancement (4.8%) of the H-3 signal indicates H-3 and H-4 are *trans*-related. Irradiation of H-2 in **9f** shows no enhancement of the H-3 proton indicating a *trans* relationship between H-2 and H-3. Similarly irradiation of H-4 in **10f** gave a small enhancement (1.4%) of H-5 and H-3 (3.5%) suggesting *trans* relationship of both H-5 and H-3 with H-4 whilst irradiation of H-2 effected a 9.4% enhancement of H-3. These data suggest that H-4 and H-5 are *trans*-related and H-2 and H-3 are *cis*-related in **10f**.

The five examples of *endo/exo*-cycloadduct mixtures comprise of four cases involving glycine imines (Table 1, entries 3, 6, 9 and 17)



Scheme 1.

Table 1
Silver salt/ NEt_3 catalysed cycloaddition of **6a–f** with *E*-nitroolefins **7a–f**^a























Entry	Imine	Dipolarophile	Cycloadduct	Ag salt	Time (h)	Yield ^b (%)
1	6a	7a	 9a	AgOAc	18	80
2	6d	7a	 9b	AgOAc	18	72
3	6a	7b	 9c	AgOAc	18	95 ^c
4	6b	7b	 9d	Ag ₂ O	18	60
5	6c	7b	 9e	Ag ₂ O	18	60
6	6d	7b	 9f	Ag ₂ O	18	95 ^d
7	6e	7b	 9g	Ag ₂ O	18	72
8	6f	7b	 9h	Ag ₂ O	18	62
9	6a	7c	 9i	Ag ₂ O	16	42 ^e

Table 1 (continued)

Entry	Imine	Dipolarophile	Cycloadduct	Ag salt	Time (h)	Yield ^b (%)
10	6b	7c		Ag ₂ O	17	91
11	6d	7c		AgOAc	16	82
12	6e	7c		Ag ₂ O	18	65
13	6a	7d		AgOAc	15	87
14	6b	7d		AgOAc	18	80
15	6e	7d		AgOAc	16	78
16	6d	7d		AgOAc	22	98
17	6a	7e		AgOAc	16	90 ^c
18	6b	7e		Ag ₂ O	16	91
19	6c	7e		Ag ₂ O	17	70

(continued on next page)

Table 1 (continued)

Entry	Imine	Dipolarophile	Cycloadduct	Ag salt	Time (h)	Yield ^b (%)
20	6d	7e		AgOAc	16	70
21	6a	7f		Ag ₂ O	16	73
22	6b	7f		AgOAc	18	78 ^c

^a Toluene, NEt₃ (1.5 equiv), Ag₂O (10 mol %) or AgOAc (1.5 equiv), 25 °C.

^b Isolated yield.

^c *endo/exo* mixture (3:1).

^d *endo/exo* mixture (5:1).

^e *endo/exo* mixture (2:1).




Figure 1.

and one involving an alanine imine (entry 22). In the former case we hypothesise that π -stacking of the electron rich C(3)-Ar substituent and the C(2)-ester carbonyl group lowers the *exo*-transition state energy sufficiently to make it competitive. Factors favouring the *exo* isomer in the latter case (entry 22) were hypothesised to arise from coordination of the excess AgOAc to the pyridine N-atom thereby inflating its steric interaction with the C2-methyl group. In accord with this when 10 mol % Ag₂O was used as catalyst only the *endo* isomer was obtained in 78% yield together with a trace amount of Michael adduct.

4. Cycloaddition of imines **12a–f**^{3b} of homoserine lactone **11**

We extended our studies to spiro nitropyrrolidines employing metallo-azomethine ylide formation from aldimines of cyclic α -amino ester **11** using a combination of AgOAc in MeCN or Ag₂O in toluene with NEt₃. Imines of a range of aldehydes (aryl, heteroaryl, aliphatic) were examined to explore the diversification of the metallo-azomethine ylide cycloaddition. In some cases imines of long chain aliphatic aldehydes were used to increase the lipophilicity of the cycloadducts. The aryl **12a–c** and aliphatic **12d–j** imines were employed in cycloadditions with a range of nitrostyrenes (Table 2).

Imines **12a–c** reacted with various nitrostyrenes in acetonitrile in the presence of triethylamine and AgOAc to give mixtures of **14a–c** (major) and **15a–c** (minor) cycloadducts in 59–83% yield (Scheme 2; Table 2, entries 1–3). The isomer ratio varied from 4.5:1


to 2:1 depending on the aryl group present in the imines **12a–c**. *Endo*-cycloadducts **14** are formed from metallo-dipole **13** via *endo*-transition states. Cycloadducts **15** arise by the base catalysed epimerisation of **14**. Fejes et al.¹⁶ reported similar epimerised cycloadducts due to the strongly activated nature of the proton (low pK_a) adjacent to the nitro group. Cossío et al.^{10b} carried out similar cycloadditions with *trans*-nitrostyrene using LiClO₄ as catalyst and proposed a stepwise mechanism for the formation of this type of cycloadduct.

In order to rule out formation of **15** by a non-concerted cycloaddition, the major isomer **14a** was subjected to base catalysed isomerisation, with the following results. Et₃N, AgOAc, acetonitrile, 25 °C, 48 h gave a 3:1 mixture of **14a** and **15a**. The same ratio of isomers was obtained by changing the base to *i*-Pr₂NEt. In the original reaction, carried out in acetonitrile in the presence of AgOAc and NEt₃, the ratio of the isomers was 3:1 after 4 h and 16 h. The observation of the same isomer ratio in both the original reaction and base catalysed isomerisation of major isomer **14a** is compelling evidence that the formation of **15a** occurs by equilibration of **14a** via **16**. The pK_a of the C-3 proton is expected to be ca. 10 while the pK_a 's of the protonated amines are also approximately 10. Equilibrium is reached between the two stereoisomers with steric factors favouring **14a** as the major isomer (Scheme 3). The structure and relative stereochemistry of the cycloadducts **14a** and **15a** was partly established by ¹H NMR, 2D-COSY_{H–H} and NOE studies (see Section 5). Subsequently X-ray crystallographic studies firmly established the stereochemical relationships (Figs. 2 and 3).

Aliphatic aldimines **12d–j** underwent Ag₂O catalysed cycloaddition with *trans*-nitrostyrene in toluene in the presence of NEt₃ to afford the corresponding *endo*-cycloadducts **14d–j** in 42–85% yield (Table 3, entries 1–7). Cycloadducts **14e.g–j** comprised 1:1 mixtures of racemic diastereomers (due to the chiral centre present in the side chain) and it was possible to separate both isomers in the case of **14i** using silica gel chromatography. Cycloadducts **14f** comprised an inseparable 1:1 mixture of chiral diastereomers. In all cases the cycloaddition was regio- and stereoselective and involved only the *E,E*-dipole **13** (Scheme 2). The stereochemistry of the cycloadducts **14d–j** was established by comparison of their ¹H NMR spectra with those of the previously described analogues.^{3b}

Table 2Catalysed cycloaddition of imines **12a–c** with *E*-nitrostyrene using AgOAc in MeCN^a


Entry	Imine	R	Time (h)	Cycloadduct	Epimer ratio	Yield ^b (%)
1 ^a	12a		4		3:1	73
2 ^a	12b		4		2:1	59
3 ^a	12c		24		4.5:1	83

^a Acetonitrile, NEt₃ (1.1 mol equiv), AgOAc (1.5 mol equiv), 25 °C, 4–24 h.^b Isolated yield.

5. Reduction of nitro compounds to amines

Several attempts at reducing the nitro moiety to the amine based on the literature methods (ammonium formate, 10% Pd/C in dry methanol,¹⁷ metal acid combinations, e.g., SnCl₂/AcOH in methanol,¹⁸ In/HCl in aqueous THF,¹⁹ Zn/concd HCl, Fe/AcOH²⁰) failed. However, the reduction of the nitro group to amine was successful using Zn/ethanol/concd HCl after protecting the NH of the pyrrolidine ring as the *N*-acetyl derivative^{8b} (Scheme 4).

The reaction of the 3:1 mixture of thienyl cycloadducts **9q** and **10q** with acetic anhydride (11 mol equiv) in pyridine at 0 °C to room temperature gave a 1.5:1 mixture of *N*-acetyl derivatives **16a** and **16b** in 66% yield. The two *N*-acetylated isomers were separated by column chromatography. Close examination of the *major* product **16a** showed that it had undergone epimerisation at C-4. Thus the



¹H and ¹³C NMR spectra were consistent with the general structure of both *N*-acetyl derivatives, but NOE experiments (Fig. 4) were necessary to assign the relative disposition of the substituents.

Irradiation of 3-H and 4-H in compound **16a** effects a 14.3 and 14.2% enhancement of 4-H and 3-H, respectively, suggesting a *cis* relationship between them. Irradiation of 2-H produced a 10.3% enhancement of the thienyl 3'-H. Finally, irradiation of the methyl group of the *N*-acetyl group produced a 3.7% enhancement of 5-H but no enhancement of 2-H establishing that the *major* solution phase conformer of the amide group is as shown in Figure 4, supporting the relative disposition shown.

Acid/base catalysed epimerisation occurred at C-4 of the *major* isomer *endo*-**9q**, facilitated by the low pK_a of the 4-H, to provide **16a**. The C-4 epimerisation was confirmed by the X-ray crystal structure of **16a** (Fig. 5), which shows the naphthyl ring and the ester group on one face of the pyrrolidine ring and the nitro group and the thienyl ring on the opposite side. Additionally, distances and dihedral angles were calculated from the X-ray structure (Fig. 5) to add further proof of the relative disposition of the substituents on the pyrrolidine ring: 2-H–3'-H=2.4205 Å and 12.18°, establishing that the 3-(2'-thienyl) group is orthogonal to the plane on the pyrrolidine ring. It was also found that in this crystal structure there is a disorder in the thiophene ring and in about half the molecules in the crystal the thiophene ring is rotated 180°, so that the sulfur occupies the position of C-3' as shown in Figure 5.

The X-ray crystal structure shows that the pyrrolidine ring of compound **16a** is in the shape of an envelope where C-4, bearing the nitro group, is now the atom out of the plane (pointing downwards on the left side of the 'stick' model in Figure 6) formed by N, C-2, C-3 and C-5 of the pyrrolidine ring. Calculated values for the dihedral angles from the X-ray crystal structure of **16a** are: 2-H–C-




Figure 2. X-ray crystal structure of **14a**.

2-C-5-5-H=150.65°, 5-H-C-5-C-4-4-H=−36.69° and 4-H-C-4-C-3-3-H=−98.55°. The *N*-acetyl group remains in the same plane of those four atoms with the methyl group oriented towards C-5. Thus the solid-state orientation of the amide matches that established for the solution phase from the NOE data. The 4-nitro group has a pseudo axial disposition while the 3-(2'-thienyl), 5-(2'-naphthyl) rings and 2-methyl ester group are pseudo equatorial. The 3-(2'-thienyl) and 5-(2'-naphthyl) rings are orthogonal to the plane formed by N, C-2, C-3 and C-5 (Fig. 6).

The relative stereochemistry of the substituents' in the *minor* isomer **16b** was assigned in the same way from NOE experiments. Irradiation of 3-H effected a 13.0% enhancement of 2-H, suggesting a *cis* relationship between them, and a 6.3% enhancement of 5-H. Irradiation of 4-H produced a 9.6% enhancement of the thienyl 4'-H. Finally, irradiation of 5-H led to a 4.5% enhancement of the methyl group of the *N*-acetyl group, suggesting the relative disposition shown in Figure 7 and establishing the same preferred amide orientation in both *major* and *minor* isomers.

The relative disposition of the substituents in compound **16b** was confirmed by an X-ray crystal structure (Fig. 8), which showed the 5-(2'-naphthyl) ring, 3-(2'-thienyl) ring and ester group are on the same face of the pyrrolidine ring. Calculated values for the dihedral angles from the X-ray crystal structure of **16b** also provide further data on the relative orientation of the substituents: 5-H-C-5-C-2-2-H=34.13°, 4-H-C-4-C-5-5-H=−168.69° and 3-H-C-3-C-4-4-H=158.78°.

As in compound **16a** the 3-(2'-thienyl) and the 5-(2'-naphthyl) rings in compound **16b** are orthogonal to the pyrrolidine ring, and the methyl group of the acetyl group is oriented towards C-5 as shown in Figure 9a.

The preference for orientation (a) (Fig. 9) might be dipole–dipole interaction of the amide and ester carbonyl groups (Fig. 10). Calculated distances, from the X-ray structures, confirm the




Figure 3. X-ray crystal structure of **15a**.

proximity between the pairs of carbonyl carbon atoms and the corresponding oxygen atoms. Thus for **16a** the O (carbonyl ester)–C (carbonyl amide) distance is 3.1914 Å, whilst the O (carbonyl amide)–C (carbonyl ester) distance is 3.0204 Å. In **16b** the O (carbonyl ester)–C (carbonyl amide) distance is 3.4971 Å and the O (carbonyl amide)–C (carbonyl ester) distance is 3.0731 Å. These data show that the mutual orientation of the *N*-acetyl groups and ester groups are consistent with π -stacking in a manner that is dictated by dipole–dipole interaction (Fig. 10).

In **16b** C-4, bearing the nitro group, is the atom out of the plane pointing upwards on the right side of the 'stick' model (Fig. 11) formed by N, C-2, C-3 and C-5 of the pyrrolidine ring, whilst the *N*-acetyl group is in the same plane as these four atoms. The 4-nitro group has a pseudo equatorial disposition *trans* to the 3-(2'-thienyl), 5-(2'-naphthyl) rings and the 2-ester group. These last three substituents are in pseudo equatorial disposition minimising the axial interactions. The 3-(2'-thienyl) and 5-(2'-naphthyl) rings are orthogonal to the plane formed by N, C-2, C-3 and C-5 of the pyrrolidine ring (Fig. 11).

Note that because of C-4 epimerisation compounds **16a** and **16b** no longer have an *endo/exo* relationship.

To probe the generality of C-4 epimerisation two further examples were studied using the same reaction conditions but this time starting from the single *endo*-cycloadducts *exo*-**9c** and *endo*-**9i** (Scheme 4). These gave exclusively the *N*-acylated epimerised products **17a,b** in 90–93% yield.

In both cases the relative disposition of the substituents in the *N*-acylated derivatives **17a** and **17b** were determined by NOE experiments. It was concluded that the nitro group and the C-3 aryl ring are *cis*-related in both compounds, and that there is a *trans* relationship between the biphenyl/naphthyl rings and the nitro groups. Thus epimerisation at C-4 in the course of the *N*-acetylation reaction appears to be general. In the case of *endo*-**9i** the acetylation not only occurred at the pyrrolidine NH, but also at the phenolic OH.

NOE studies on **17b** are summarised in Figure 12. Thus irradiation of 4-H produced a 9.15% enhancement of 3-H, but only a 3.6% enhancement of 5-H. Likewise irradiation of 3-H caused a 9.0% enhancement of 4-H, whilst irradiation of 5-H gave a 3.7% enhancement of 4-H, establishing a *cis* relationship between 3-H and 4-H, and a *trans* relationship between 4-H and 5-H. Finally irradiation of 5-H also produced a 7.7% enhancement of the methyl of the *N*-acetyl group and no enhancement of 2-H establishing the same orientation of the amide as observed previously.















Reduction of **16a** and **16b** was carried out with zinc dust (17 mol equiv) in 50:1 ethanol/concd hydrochloric acid at 40–50 °C, then for 12 h at reflux giving the corresponding amino derivatives **18a** and **18b** in 88–95% yield.

The relative stereochemistry of the pyrrolidine ring substituents in the amino derivative **18a** was assigned from NOE data. (Fig. 13) Irradiation of 3-H effects an 8.6% enhancement of 4-H, suggesting a *cis* relationship between them, whilst an 8.8% enhancement of the thienyl 3'-H occurred on irradiating 2-H. Finally, irradiation of the methyl of the *N*-acetyl group gave a 2.3% enhancement of 5-H and no enhancement of 2-H suggesting the relative stereochemistry and conformation of the *N*-acetyl group shown in Figure 13.

6. Conclusions

In conclusion we have shown that (i) *in situ* generated argento azomethine ylides undergo concerted cycloaddition to *E*-nitrostyrenes via *endo*-transition states in good yield, (ii) the pyrrolidine ring has an envelope conformation with the C-4 nitro bearing carbon the out-of-plane atom, (iii) *N*-acetylation with Ac₂O is accompanied by C-4 epimerisation (iv) a combination of NOE solution studies and X-ray crystallography show a dipole–dipole stacking interaction involving the C-2 ester and *N*-acetyl carbonyl groups with the methyl group of the latter oriented towards the C-5 aryl substituent

Table 3
Catalysed cycloaddition of imines **12d–j** with *E*-nitrostyrenes using Ag₂O/NEt₃ in toluene^a

Entry	Imine	R	Time (h)	Cycloadduct	dr	Yield (%) ^b
1	12d		1		—	74
2	12e		1		1:1	51
3	12f		4		1:1	42
4	12g		3		1:1	58
5	12h		4		1:1	85
6	12i		5		1:3	72
7	12j		4		1:1	59

^a Toluene, NEt₃ (1.1 mol equiv), Ag₂O (10 mol%), 25 °C, 1–5 h.

^b Isolated yield.




and (v) reduction of the C-4 nitro group with Zn/HCl/EtOH affords the corresponding amines.

7. Experimental

7.1. General

Melting points were determined on a Reichert hot-stage or Buchi B-545 apparatus and are uncorrected. Microanalysis was

performed using a Carlo Erba MOD 1108 or 11016 instrument. Mass spectral data were recorded on a V.G.-AutoSpec instrument operating at 70 eV. Accurate molecular weights were recorded on a Micromass LCT KALIII electrospray (ES) machine. Infrared spectra were recorded either on KBr discs or on films, prepared by evaporation of a dichloromethane solution, on a Nicolet Magna FT-IR or Nicolet 460ESP FT-IR Spectrometer. Nuclear magnetic resonance spectra were recorded at 250 MHz on a Bruker AC250 instrument or at 300 MHz on a Bruker DPX300 or at 500 MHz on a Bruker



DRX500 instrument. Chemical shifts (δ) are given in parts per million (ppm). Deuteriochloroform was used as the solvent unless otherwise stated. The following abbreviations are used: s=singlet, d=doublet, t=triplet, q=quartet, dd=double doublet, dt=double triplet, ddd=double double doublet, m=multiplet, br=broad, app=apparent. Flash chromatography was performed either with silica gel 60 (230–400 mesh) or with 10 g/20 g SPE-Anachem SI




Figure 6. Stick model of **16a**.




Figure 7. NOE data of compound **16b**.




Figure 8. X-ray crystal structure of **16b**.

Mega Bond-Elut. All solvents were purified according to standard procedures. The term ether refers to diethyl ether. Analytical grade anhydrous silver salts were used as purchased. In all reactions




Figure 9. Two possible orientations of the *N*-acetyl.




Figure 10. Possible dipole–dipole interaction.




Figure 11. Model of **16b**.




Figure 12. NOE data of compound **17b**.




Figure 13. NOE data of compound **18a**.

involving silver(I) salts the reaction flask was covered with aluminium foil.


7.2. General procedure for silver(I) catalysed cycloaddition reactions

The appropriate aldimine (1 mol equiv), triethylamine, dipolarophile (1 mol equiv) and silver acetate (1.5 mol equiv) were mixed in freshly distilled acetonitrile. Silver oxide (10 mol %) as metal catalyst and toluene (dried over sodium wire) as solvent were used in the case

of aliphatic aldimines. The resulting suspension was stirred for an appropriate period at room temperature (monitored by TLC and ^1H NMR). After completion of the reaction the mixture was quenched with saturated aqueous ammonium chloride and extracted with ether or dichloromethane ($2\times$). The dried (magnesium sulfate) organic layer was concentrated under reduced pressure. The ratio of any isomers present in the residue was calculated from the integrals of appropriate peaks in the ^1H NMR spectrum. Flash chromatography afforded the individual stereoisomers when present.

7.2.1. Methyl 3-(9-anthryl)-5-(2-naphthyl)-4-nitro-prolinate (**9a**)

Obtained from imine **6a** (227 mg, 1 mmol), *E*-nitrostyrene **7a** (249 mg, 1 mmol), triethylamine (0.21 mL, 1.5 mmol) and silver acetate (250 mg, 1.5 mmol) in toluene (20 mL) over 18 h. Purification was achieved by triturating with ether and filtering to afford the product (380 mg, 80%) as a pale yellow amorphous solid, mp 130–132 °C. Found: C, 75.35; H, 5.15; N, 5.75. $\text{C}_{30}\text{H}_{24}\text{N}_2\text{O}_4$ requires: C, 75.60; H, 5.10; N, 5.90%; δ (^1H , 250 MHz): 8.51 (s, 1H, ArH), 8.00–7.50 (m, 15H, ArH), 6.17 (dd, 1H, *J* 6.2 and 7.5 Hz, 4-H), 6.01 (dd, 1H, *J* 6.2 and 9.7 Hz, 3-H), 5.76 (d, 1H, *J* 7.5 Hz, 5-H), 4.81 (d, 1H, *J* 9.7 Hz, 2-H), 3.60 (br t, 1H, *J* 9.7 Hz, NH) and 3.48 (s, 3H, OMe); δ (^{13}C): 172.4 (CO), 133.8, 133.5, 132.6 (C_q), 129.7, 128.9, 128.6, 128.2 ($2\times$ ArCH), 127.6, 127.0 (C_q), 126.9, 126.4, 124.7, 123.5 ($2\times$ ArCH), 97.7 (C₄), 68.2 (C₂), 66.1 (C₃), 52.9 (C₅) and 50.8 (OCH₃); ν_{max} (KBr): 3057, 1737, 1557, 1266, 1214 and 756 cm^{-1} ; *m/z* (%): 476 (M^{++} , 20), 427 (20), 370 (50) and 202 (100); *m/z* (ES^+): 500 ($\text{M}^{++}+1+\text{Na}$), 499 ($\text{M}^{++}+\text{Na}$), 477 ($\text{M}^{++}+1$, 100).



NOE data for **9a**:

Irradiated proton	% Enhancement				
	H-1	H-2	H-3	H-4	H-5
H-2	2.5	—	—	—	3.2
H-3	0.8	—	—	—	—
H-4	—	—	—	—	6.0
H-5	—	4.2	—	8.8	—


7.2.2. Methyl 3-(9-anthryl)-5-(1,1'-biphenyl-4-yl)-4-nitro-prolinate (**9b**)

Obtained from imine **6d** (253 mg, 1 mmol), *E*-nitrostyrene **7a** (249 mg, 1 mmol), triethylamine (0.21 mL, 1.5 mmol) and silver acetate (250 mg, 1.5 mmol) in toluene (20 mL) over 18 h. Purification by flash chromatography eluting with DCM/hexane (20%) afforded the product (361 mg, 72%) as a pale yellow powder, mp 270–272 °C. Found: C, 76.55; H, 5.25; N, 5.45. $\text{C}_{32}\text{H}_{26}\text{N}_2\text{O}_4$ requires: C, 76.50; H, 5.20; N, 5.55%; δ (^1H , 250 MHz): 8.50 (s, 1H, ArH), 8.34–7.97 (m, 5H, ArH), 7.95–7.80 (m, 3H, ArH), 7.75–7.39 (m, 7H, ArH), 7.30–7.05 (m, 2H, ArH), 6.17 (dd, 1H, *J* 6.3 and 7.5 Hz, 4-H), 6.00 (dd, 1H, *J* 6.3 and 9.8 Hz, 3-H), 5.74 (d, 1H, *J* 7.5 Hz, 5-H), 4.81 (d, 1H, *J* 9.8 Hz, 2-H), 3.48 (s, 3H, OMe) and 2.35 (s, 1H, NH); δ (^{13}C): 172.4 (CO), 133.8, 133.5, 132.6 (C_q), 129.7 ($2\times$ ArCH), 129.5 ($2\times$ C_q), 128.9 ($2\times$ ArCH), 128.6 ($4\times$ ArCH), 128.2 ($2\times$ ArCH), 127.6 (C_q), 127.0 ($2\times$ ArCH), 126.9 (C_q), 126.4 ($2\times$ ArCH), 125.7 (C_q), 124.7, 123.5 ($2\times$ ArCH), 97.7 (C₄), 68.2 (C₂), 66.1 (C₃), 52.9 (C₅) and 50.8 (OCH₃); ν_{max} (KBr): 3353, 3053, 3031, 2953, 2849, 1737, 1557, 1438, 1231, 891, 765, 730 and 700 cm^{-1} ; *m/z* (ES^+): 502 (M^{++} , 100).

7.2.3. Methyl 3-(1*H*-indol-3-yl)-5-(2-naphthyl)-4-nitro-prolinate (**9c** and **10c**)

Obtained from imine **6a** (227 mg, 1 mmol), *E*-nitrostyrene **7b** (188 mg, 1 mmol), triethylamine (0.21 mL, 1.5 mmol) and silver acetate (250 mg, 1.5 mmol) in toluene (20 mL) over 18 h. Purification by cartridge column SPE-Anachem 20 g SI Mega Bond-Elut eluting with 100% hexane to 100% ethyl acetate gradient elution afforded first *endo*-**9c** (291 mg, 70%), followed by *exo*-**10c** (104 mg, 25%).


endo-**9c**. Obtained as colourless plates, mp 163–165 °C. Found: C, 69.25; H, 5.15; N, 9.85. C₂₄H₂₁N₃O₄ requires: C, 69.40; H, 5.10; N, 10.10%; δ (¹H, 300 MHz): 10.50 (br s, 1H, indole NH), 7.88–7.11 (m, 12H, ArH), 5.49 (dd, 1H, *J* 2.8 and 5.9 Hz, 4-H), 5.11 (dd, 1H, *J* 5.9 and 10.9 Hz, 5-H), 4.57 (dd, 1H, *J* 3.0 and 7.2 Hz, 3-H), 4.44 (2×overlapping d, 1H, *J* 9.0 and 7.0 Hz, 2-H), 3.82 (s, 3H, OMe) and 3.62 (t, 1H, *J* 10.9 Hz, NH); δ (¹³C): 172.6 (CO), 137.1, 133.6, 133.5, 132.0 (C_q), 128.9, 128.5, 128.0 (ArCH), 126.8 (2×ArCH), 126.3 (C_q), 125.9, 124.4, 123.5, 122.3, 120.8, 119.0 (ArCH), 114.0 (C_q), 112.1 (ArCH), 96.4 (C₄), 67.8 (C₂), 65.9 (C₃), 53.1 (C₅) and 48.7 (OCH₃); ν_{\max} (KBr): 3328, 3057, 1733, 1552, 1384, 1215, 1112 and 747 cm⁻¹; *m/z* (ES): 416 (M⁺⁺¹), 414 (M^{+–1}).



NOE data for **9c**:

Irradiated proton	% Enhancement				
	H-3	H-4	H-5	H-2'	Aryl
H-1	6.4	2.1	—	—	—
H-2	—	—	4.1	7.7	3.1
H-3	—	3.9	—	2.7	3.5
H-4	4.8	—	9.1	—	2.7, 4.0
H-5	4.6	12.8	—	—	5.7, 2.8

exo-**10c**. Obtained as pale orange plates, mp 207–209 °C. Found: C, 69.45; H, 5.15; N, 10.00. C₂₄H₂₁N₃O₄ requires: C, 69.40; H, 5.10; N, 10.10%; δ (¹H, 300 MHz, CDCl₃+2 drops DMSO): 9.87 (br s, 1H, indole NH), 7.85–6.93 (m, 12H, ArH), 5.27 (t, 1H, *J* 8.1 Hz, 4-H), 4.86 (t, 1H, *J* 8.1 Hz, 5-H), 4.65 (t, 1H, *J* 8.1 Hz, 3-H), 4.51 (dd, 1H, *J* 6.7 and 8.1 Hz, 2-H), 3.06 (s, 3H, OMe) and 2.92 (dd, 1H, *J* 6.7 and 8.1 Hz, NH); δ (¹³C, CDCl₃+2 drops DMSO-*d*₆): 172.9 (CO), 136.6 (C_q), 136.2 (2×C_q), 133.7, 133.5, (C_q), 129.3, 128.4, 128.0, 126.8, 126.7, 126.5, 124.6, 122.7, 122.3, 119.7, 118.7, 111.9 (ArCH), 109.7 (C_q), 95.6 (C₄), 67.8 (C₂), 63.9 (C₃), 51.9 (C₅) and 46.3 (OCH₃); ν_{\max} (KBr): 3418, 3356, 2948, 1742, 1543, 1361, 1204 and 739 cm⁻¹; *m/z* (ES): 417 (M⁺⁺), 416 (M⁺⁺¹, 100).



NOE data for *exo*-**10c**:

Irradiated proton	% Enhancement					
	H-2	H-3	H-4	H-5	H-2'	Aryl
H-1	5.4	—	—	—	5.8	4.8, 4.0
H-2	—	9.4	—	3.5	—	—

(continued)

(continued)

Irradiated proton	% Enhancement					Aryl
	H-2	H-3	H-4	H-5	H-2'	
H-3	11.8	—	3.6	5.2	2.5	9.3
H-4	—	3.5	—	1.5	9.2	4.1, 4.9
H-5	3.6	4.3	—	—	—	10.3, 3.5

7.2.4. Methyl 3-(1*H*-indol-3-yl)-2-methyl-5-(2-naphthyl)-4-nitro-prolinate (**9d**)

Obtained from imine **6b** (241 mg, 1 mmol), *E*-nitrostyrene **7b** (188 mg, 1 mmol), triethylamine (0.21 mL, 1.5 mmol) and silver oxide (30 mg, 0.13 mmol) in toluene (20 mL) over 18 h. Purification by triturating with ether and filtering afforded the product (258 mg, 60%) as a pale orange amorphous solid, mp 190–193 °C. Found: C, 70.05; H, 5.25; N, 9.80. C₂₅H₂₃N₃O₄ requires: C, 69.90; H, 5.40; N, 9.80%; δ (¹H, 250 MHz, CDCl₃+2 drops DMSO-*d*₆): 10.33 (br s, 1H, indole NH), 7.42 (s, 1H, ArH), 7.33–6.50 (m, 11H, ArH), 5.43 (br t, 1H, *J* 7.7 Hz, 4-H), 4.80 (br t, 1H, *J* 9.1 Hz, 5-H), 4.35 (br d, 1H, *J* 7.7 Hz, 3-H), 3.26 (s, 3H, OMe), 3.09 (br d, 1H, *J* 9.1 Hz, NH), 0.75 (s, 3H, CH₃); δ (¹³C, CDCl₃+2 drops DMSO): 175.5 (CO), 136.6, 133.9, 133.4, 133.2 (C_q), 128.4, 127.9 (ArCH), 127.3 (C_q), 126.6 (2×ArCH), 126.3, 125.1, 123.4, 122.1, 119.6, 118.9, 112.1 (ArCH), 109.9 (C_q), 96.6 (C₄), 68.6 (C₂), 64.4 (C₃), 53.1 (C₅), 50.2 (OCH₃) and 21.9 (CH₃); ν_{\max} (KBr): 3070, 3425, 1722, 1544, 1456, 1395, 1139, 855, 819 and 747 cm⁻¹; *m/z* (ES): 430 (M⁺⁺¹, 100), 428 (M^{+–1}, 100).

7.2.5. Methyl 2-benzyl-3-(1*H*-indol-3-yl)-5-(2-naphthyl)-4-nitro-prolinate (**9e**)

Obtained from imine **6c** (377 mg, 1 mmol), *E*-nitrostyrene **7b** (188 mg, 1 mmol), triethylamine (0.21 mL, 1.5 mmol) and silver oxide (30 mg, 0.13 mmol) in toluene (20 mL) over 18 h. Purification by flash chromatography eluting with 19:1 v/v dichloromethane/hexane afforded the product (303 mg, 60%) as pale yellow needles, mp 143–146 °C. Found (HRMS, M^{++Na}): 528.1899. C₃₁H₂₇N₃O₄Na requires: 528.1899; δ (¹H, 250 MHz): 8.30 (s, 1H, indole NH), 7.98 (s, 1H, ArH), 7.85–7.77 (m, 4H, ArH), 7.49–7.42 (m, 4H, ArH), 7.26–7.10 (m, 8H, ArH), 5.81 (dd, 1H, *J* 5.0 and 7.1 Hz, 4-H), 5.46 (dd, 1H, *J* 7.1 and 9.3 Hz, 5-H), 4.90 (d, 1H, *J* 5.0 Hz, 3-H), 3.75 (s, 3H, OMe), 3.53 (d, 1H, *J* 9.3 Hz, NH) and 2.86 (S_{AB}, 2H, CH₂); δ (¹³C): 174.2 (CO), 136.7, 136.1, 133.4, 133.2, 133 (C_q), 130.0, 128.9, 128.4, 128.2, 128.0, 127.7 (ArCH), 127.3 (C_q), 126.8, 126.4, 126.2, 124.6, 122.8, 120.4, 119.2, 111.6 (ArCH), 111.0 (C_q), 96.8 (C₄), 73.1 (C₂), 65.2 (C₃), 52.4 (C₅), 50.6 (OCH₃) and 40.6 (CH₂); ν_{\max} (KBr): 3377, 3057, 1727, 1555, 1457, 1430, 1370, 1200, 819, 749 and 707 cm⁻¹; *m/z* (ES⁺): 530 (M^{++2+Na}), 529 (M^{++1+Na}), 506 (M⁺⁺¹, 100); (ES⁻): 505 (M⁺), 504 (M^{+–1}, 100).

7.2.6. Methyl 5-(1,1'-biphenyl-4-yl)-3-(1*H*-indol-3-yl)-4-nitro-prolinate (**9f** and **10f**)

Obtained from imine **6d** (253 mg, 1 mmol), *E*-nitrostyrene **7b** (188 mg, 1 mmol), triethylamine (0.21 mL, 1.5 mmol) and silver oxide (30 mg, 0.13 mmol) in toluene (20 mL) over 18 h. Purification by SPE-Anachem 20 g SI Mega Bond-Elut cartridge using 100% hexane to 100% ethyl acetate gradient elution afforded first *endo*-**9f** (304 mg, 69%), followed by *exo*-**10f** (114 mg, 26%).

endo-**9f**. Obtained as colourless plates, mp 152–154 °C. Found: C, 70.80; H, 5.30; N, 9.25. C₂₆H₂₃N₃O₄ requires: C, 70.75; H, 5.25; N, 9.50%; δ (¹H, 300 MHz): 8.30 (br s, 1H, indole NH), 7.66–7.19 (m, 14H, ArH), 5.43 (dd, 1H, *J* 2.6 and 6.0 Hz, 4-H), 4.97 (d, 1H, *J* 6.0 Hz, 5-H), 4.58 (dd, 1H, *J* 2.6 and 6.8 Hz, 3-H), 4.43 (d, 1H, *J* 6.8 Hz, 2-H), 3.85 (s, 3H, OMe) and 3.56 (m, 1H, NH); δ (¹³C): 172.6 (CO), 141.8, 140.7, 137.1, 133.7 (C_q), 129.2 (2×ArCH), 127.9 (ArCH), 127.8 (2×ArCH), 127.5 (2×ArCH), 127.2 (2×ArCH), 126.3 (C_q), 123.5 (indole C₂), 122.3 (indole C₅), 120.8 (indole C₄), 118.9 (indole C₆),

113.9 (indole C_{3'}), 112.1 (indole C_{7'}), 96.5 (C₄), 67.5 (C₂), 65.9 (C₃), 53.1 (C₅) and 48.6 (OCH₃); ν_{\max} (KBr): 3294, 3038, 2953, 2903, 1735, 1542, 1372, 1212, 1095, 835, 765, 745 and 701 cm⁻¹; m/z (ES⁺): 464 (M⁺⁺+Na), 443 (M⁺⁺+2), 442 (M⁺⁺+1, 100); (ES⁻): 441 (M⁺), 440 (M⁺⁺-1, 100).

exo-10f. Obtained as pale orange plates, mp 171–173 °C. Found: C, 70.50; H, 5.10; N, 9.25. C₂₆H₂₃N₃O₄ requires: C, 70.75; H, 5.25; N, 9.50%; δ (¹H, 300 MHz): 8.21 (br s, 1H, indole NH), 7.67–7.06 (m, 14H, ArH), 5.31 (t, 1H, J 7.9 Hz, 4-H), 4.88 (d, 1H, J 7.9 Hz, 5-H), 4.76 (t, 1H, J 7.9 Hz, 3-H), 4.63 (d, 1H, J 7.9 Hz, 2-H), 3.18 (s, 3H, OMe) and 2.92 (br s, 1H, NH); δ (¹³C): 172.8 (CO), 142.1, 140.9, 137.6, 136.4, 130 (C_q), 129.2 (2×ArCH), 128.1 (2×ArCH), 127.9 (C_q), 127.6 (2×ArCH), 127.5 (2×ArCH), 123.1, 122.2, 120.4, 119.2 (indole C_{2'-6'}), 111.6 (indole C_{7'}), 111.3 (C_{3'}), 95.8 (C₄), 67.6 (C₂), 64.1 (C₃), 52.1 (C₅) and 46.2 (OCH₃); ν_{\max} (KBr): 3382, 3059, 2954, 2873, 1743, 1547, 1362, 1200, 909, 853, 768, 734 and 702 cm⁻¹; m/z (ES⁺): 443 (M⁺⁺+2), 442 (M⁺⁺+1, 100); (ES⁻): 441 (M⁺), 440 (M⁺⁺-1, 100).

7.2.7. Methyl 5-(1,1'-biphenyl-4-yl)-3-(1H-indol-3-yl)-2-methyl-4-nitro-prolinate (**9g**)

Obtained from imine **6e** (267 mg, 1 mmol), *E*-nitrostyrene **7b** (188 mg, 1 mmol), triethylamine (0.21 mL, 1.5 mmol) and silver oxide (30 mg, 0.13 mmol) in toluene (20 mL) over 18 h. Purification by flash chromatography eluting with 9:1 v/v dichloromethane/hexane afforded the product (327 mg, 72%) as pale orange plates, mp 132–136 °C. Found: C, 71.15; H, 5.30; N, 9.15. C₂₇H₂₅N₃O₄ requires: C, 71.20; H, 5.55; N, 9.20%; δ (¹H, 250 MHz): 8.31 (br s, 1H, indole NH), 7.69–7.14 (m, 14H, ArH), 5.75 (dd, 1H, J 6.5 and 7.5 Hz, 4-H), 5.21 (d, 1H, J 7.5 Hz, 5-H), 4.90 (d, 1H, J 6.5 Hz, 3-H), 3.86 (s, 3H, OMe) and 1.32 (s, 3H, CH₃); δ (¹³C): 175.7 (CO), 142.0, 140.8, 136.5, 134.9 (C_q), 129.2 (2×ArCH), 127.9 (ArCH), 127.8, 127.5 (3×ArCH), 127.4 (C_q), 123.1, 122.8, 120.6, 119.5 (indole C_{2'-6'}), 111.9 (indole C_{7'}), 111.5 (C_{3'}), 96.8 (C₄), 69.0 (C₂), 64.9 (C₃), 53.4 (C₅), 50.4 (OCH₃) and 22.3 (CH₃); ν_{\max} (KBr): 3406, 3298, 3039, 1735, 1543, 1435, 1251, 1138, 1115, 846, 764, 745 and 700 cm⁻¹; m/z (% FAB): 456 (M⁺⁺+1, 80), 308 (100), 268 (85); m/z (ES⁺): 479 (M⁺⁺+1+Na), 478 (M⁺⁺+Na), 456 (M⁺⁺+1, 100); (ES⁻): 455 (M⁺), 454 (M⁺⁺-1).

7.2.8. Methyl 2-benzyl-5-(1,1'-biphenyl-4-yl)-3-(1H-indol-3-yl)-4-nitro-prolinate (**9h**)

Obtained from imine **6f** (343 mg, 1 mmol), *E*-nitrostyrene **7b** (188 mg, 1 mmol), triethylamine (0.21 mL, 1.5 mmol) and silver oxide (30 mg, 0.13 mmol) in toluene (20 mL) over 18 h. Purification by flash chromatography eluting with 9:1 v/v dichloromethane/hexane afforded the product (330 mg, 62%) as pale yellow plates, mp 174–178 °C. Found: C, 74.55; H, 5.50; N, 7.90%. C₃₃H₂₉N₃O₄ requires: C, 74.55; H, 5.50; N, 7.90%. δ (¹H, 250 MHz): 8.30 (br s, 1H, indole NH), 7.90–6.90 (m, 19H, ArH), 5.75 (dd, 1H, J 6.6 and 5.2 Hz, 4-H), 5.34 (d, 1H, J 6.6 Hz, 5-H), 4.87 (d, 1H, J 5.2 Hz, 3-H), 3.73 (s, 3H, OMe), 3.42 (br s, 1H, NH) and 2.84 (s, 2H, CH₂); δ (¹³C): 174.6 (CO), 142.1, 140.9, 137.1, 136.5, 135.1 (C_q), 130.4, 129.2, 128.5 (2×ArCH), 127.9, 127.8 (3×ArCH), 127.7 (C_q), 127.5 (2×ArCH), 127.2, 123.2, 120.8, 119.6, 111.9 (ArCH), 111.4 (C_{3'}), 97.2 (C₄), 73.4 (C₂), 65.2 (C₃), 52.9 (C₅), 50.8 (OCH₃) and 41.0 (CH₂); ν_{\max} (KBr): 3381, 3055, 2963, 1728, 1553, 1457, 1428, 1370, 1200, 819, 748 and 706 cm⁻¹; m/z (% FAB⁺): 532 (M⁺⁺+1, 80), 308 (100).


7.2.9. Methyl 3-(4-hydroxy-3-methoxyphenyl)-5-(2-naphthyl)-4-nitro-prolinate (**9i**)

Obtained from imine **6a** (227 mg, 1 mmol), *E*-nitrostyrene **7c** (195 mg, 1 mmol), triethylamine (0.21 mL, 1.5 mmol) and silver oxide (30 mg, 0.13 mmol) in toluene (20 mL) over 16 h. Trituration with 9:1 v/v dichloromethane/methanol and filtration afforded the product (177 mg, 42%) as colourless plates, mp 208–210 °C. Found: C, 65.40; H, 5.25; N, 6.50. C₂₃H₂₂N₂O₆ requires: C, 65.40; H, 5.25; N, 6.65%; δ (¹H, 300 MHz): 8.0 (br s, 1H, OH), 7.93 (d, 1H, J 8.7 Hz, ArH),

7.86 (dd, 2H, J 6.0 and 3.4 Hz, ArH), 7.72 (dd, 1H, ArH), 7.52 (dd, 2H, J 6.0 and 3.4 Hz, ArH), 6.85 (d, 1H, J 8.7 Hz, ArH), 6.78 (m, 2H, ArH), 5.70 (m, 1H, NH), 5.26 (t, 1H, J 7.7 Hz, 4-H), 4.93 (d, 1H, J 7.7 Hz, 5-H), 4.55 (d, 1H, J 8.7 Hz, 2-H), 4.35 (dd, 1H, J 8.7 and 7.7 Hz, 3-H), 3.84 (s, 3H, CO₂Me) and 3.42 (s, 3H, OMe); δ (¹H, 250 MHz, DMSO-*d*₆): 9.06 (s, 1H, OH), 7.92 (m, 4H, ArH), 7.61 (dd, 1H, J 1.5 and 8.5 Hz, ArH), 7.53 (m, 2H, ArH), 7.02 (d, 1H, J 1.8 Hz, ArH), 6.82 (dd, 1H, J 1.8 and 8.1 Hz, ArH), 6.75 (d, 1H, J 8.1 Hz, ArH), 5.71 (dd, 1H, J 5.0 and 7.9 Hz, NO₂CH), 5.22 (t, 1H, J 7.9 Hz, naphthyl-CH), 4.08 (m, 2H, H+H₂), 3.93 (t, 1H, J 7.9 Hz, phenyl-CH), 3.81 (s, 3H, CO₂Me) and 3.71 (s, 3H, OMe); δ (¹³C, DMSO-*d*₆): 172.3 (CO), 148.1, 146.4, 135.1, 133.0, 132.9, 129.2 (C_q), 128.3, 127.9, 127.8, 126.6, 126.5, 126.0, 125.7, 120.9, 115.8, 112.3 (ArCH), 96.5 (C₄), 66.5 (C₂), 65.6 (C₃), 56.1 (ArOCH₃), 54.0 (CO₂CH₃) and 52.5 (C₅); ν_{\max} (KBr): cm⁻¹; m/z (ES⁺): 423 (M⁺⁺+1, 100).

7.2.10. Methyl 3-(4-hydroxy-3-methoxyphenyl)-2-methyl-5-(2-naphthyl)-4-nitro-prolinate (**9j**)

Obtained from imine **6b** (241 mg, 1 mmol), *E*-nitrostyrene **7c** (195 mg, 1 mmol), triethylamine (0.21 mL, 1.5 mmol) and silver oxide (30 mg, 0.13 mmol) in toluene (20 mL) over 17 h. Purification by triturating with dichloromethane and filtering afforded the product (396 mg, 91%) as a pale yellow solid, mp 164–166 °C. Found: C, 65.90; H, 5.55; N, 6.40. C₂₄H₂₄N₂O₆ requires: C, 66.05; H, 5.55; N, 6.40%; δ (¹H, 250 MHz, DMSO-*d*₆): 9.07 (s, 1H, OH), 7.96–7.87 (m, 4H, ArH), 7.64–7.49 (m, 3H, ArH), 6.95 (d, 1H, J 1.9 Hz, ArH), 6.83 (dd, 1H, J 1.9 and 8.2 Hz, ArH), 6.74 (d, 1H, J 8.2 Hz, ArH), 6.27 (t, 1H, J 8.6 Hz, 4-H), 5.29 (t, 1H, J 8.6 Hz, 5-H), 4.53 (d, 1H, J 8.6 Hz, 3-H), 3.93 (d, 1H, J 8.6 Hz, NH), 3.81 (s, 3H, CO₂Me), 3.79 (s, 3H, OMe) and 1.21 (CH₃); δ (¹³C, CDCl₃+2 drops DMSO): 174.7 (CO), 147.5, 146.3, 134.0, 133.1, 132.9 (C_q), 128.0, 127.9, 127.6 (ArCH), 126.3 (C_q), 126.1, 125.0, 120.8, 115.4, 112.7 (ArCH), 95.0 (C₄), 68.3 (C₂), 63.8 (C₃), 56.1 (ArOCH₃), 56.0 (CO₂CH₃), 52.7 (C₅) and 21.4 (CH₃); ν_{\max} (KBr): 3294, 2952, 1740, 1547, 1436, 1264, 1128, 863, 832 and 746 cm⁻¹; m/z (ES⁺): 460 (M⁺⁺+1+Na), 437 (M⁺⁺+1, 100); (ES⁻): 436 (M⁺), 435 (M⁺⁺-1, 100).



NOE data for **9j**:

Irradiated proton	% Enhancement					
	H-3	H-4	H-5	Phenyl	Naph-	CH ₃
H-3	—	4.2	—	10.7	1.3, 1.4	11.8
H-4	1.9	—	4.8	7.9	2.8, 2.4	—
H-5	—	8.2	—	3.0	5.3, 4.8	3.3
CH ₃	0.4	0.8	2.0	1.8	—	—

7.2.11. Methyl 5-(1,1'-biphenyl-4-yl)-3-(4-hydroxy-3-methoxyphenyl)-4-nitro-prolinate (**9k**)

Obtained from imine **6d** (401 mg, 1.6 mmol), *E*-nitrostyrene **7c** (309 mg, 1.6 mmol), triethylamine (0.33 mL, 2.4 mmol) and silver acetate (395 mg, 2.4 mmol) in toluene (30 mL) over 16 h. Purification by triturating with 9:1 v/v ethyl acetate/hexane afforded the product (367 mg, 82%) as a colourless solid, mp 187–190 °C. HRMS (M⁺⁺+H): 449.1710. C₂₅H₂₄N₂O₆ requires: 449.1712. δ (¹H, 300 MHz, CDCl₃+2 drops DMSO-*d*₆): 7.56–7.52 (m, 4H, ArH), 7.42–7.28 (m, 5H, ArH), 6.95 (s, 1H, OH), 6.90 (d, 1H, J 7.5 Hz, ArH), 6.75 (dd, 1H, J 2.3 and 7.5 Hz, ArH), 6.74 (s, 1H, ArH), 5.70 (m, 1H, NH), 5.24 (dd, 1H, J 3.4 and 6.4 Hz, 4-H), 4.90 (dd, 1H, J 6.4 and 10.9 Hz, 5-H), 4.12 (m, 2H, 2-H+3-H), 3.87 (s, 3H, CO₂Me), 3.78 (s, 3H, OMe) and 3.32 (m, 1H, OH); δ (¹³C, CDCl₃+2 drops DMSO): 172.3 (CO), 147.8, 146.3, 130.2 (C_q), 129.1 (2×ArCH), 127.9 (ArCH), 127.7 (2×ArCH), 127.4

(2×ArCH), 127.3 (2×ArCH), 120.1, 115.9, 111.2 (ArCH), 104.4 (C_q), 97.5 (C₄), 73.1 (C₂), 67.6 (C₃), 55.5 (ArOCH₃), 53.0 (C₅) and 40.7 (OCH₃); ν_{\max} (KBr): 3459, 3254, 3008, 2956, 1739, 1601, 1555, 1457, 1438, 1367, 1204, 1008, 816, 759 and 697 cm⁻¹; m/z (ES⁺): 473 (M⁺+Na+2), 472 (M⁺+Na+1), 471 (M⁺+Na), 449 (M⁺+1, 100); (ES⁻): 448 (M⁺), 447 (M⁺-1, 100); m/z (% FAB⁺): 449 (M⁺+1, 100), 315 (50).

7.2.12. Methyl 5-(1,1'-biphenyl-4-yl)-3-(4-hydroxy-3-methoxyphenyl)-2-methyl-4-nitro-prolinate (**9l**)


Obtained from imine **6e** (267 mg, 1 mmol), *E*-nitrostyrene **7c** (195 mg, 1 mmol), triethylamine (0.21 mL, 1.5 mmol) and silver oxide (30 mg, 0.13 mmol) in toluene (20 mL) over 18 h. Purification by flash chromatography eluting with dichloromethane afforded the product (300 mg, 65%) as a pale yellow amorphous solid, mp 172–175 °C. Found: C, 67.70; H, 5.70; N, 6.35. C₂₆H₂₆N₂O₆ requires: C, 67.50; H, 5.70; N, 6.05%; δ (¹H, 300 MHz): 7.62–7.59 (m, 5H, ArH), 7.55 (m, 4H, ArH), 6.92 (m, 1H, ArH), 6.78 (m, 2H, ArH), 5.69 (t, 1H, J 7.3 Hz, 4-H), 5.12 (d, 1H, J 7.3 Hz, 5-H), 4.53 (d, 1H, J 7.3 Hz, 3-H), 3.88 (s, 6H, CO₂Me and OMe), 3.30 (m, 1H, NH) and 1.24 (s, 3H, CH₃); δ (¹³C, CDCl₃+2 drops DMSO-*d*₆): 175.1 (CO), 147.6, 146.5, 141.5, 140.6, 135.4 (C_q), 129.1 (2×ArCH), 127.8 (3×ArCH), 127.4 (2×ArCH), 127.3 (2×ArCH), 126.8 (C_q), 120.9, 115.5, 112.8 (ArCH), 104.4 (C_q), 95.6 (C₄), 68.8 (C₂), 64.3 (C₃), 56.7 (ArOCH₃), 56.3 (C₅), 53.2 (OCH₃) and 21.9 (CH₃); ν_{\max} (KBr): 3258, 1736, 1600, 1558, 1437, 1258, 1137, 853, 760 and 717 cm⁻¹; m/z (% FAB): 463 (M⁺+1, 100), 315 (95); m/z (ES⁺): 485 (M⁺+Na), 463 (M⁺+1, 100); (ES⁻): 462 (M⁺), 461 (M⁺-1, 100).

7.2.13. Methyl 3-(2-furyl)-5-(2-naphthyl)-4-nitro-prolinate (**9m**)

Obtained from imine **6a** (227 mg, 1 mmol), *E*-nitrostyrene **7d** (139 mg, 1 mmol), triethylamine (0.21 mL, 1.5 mmol) and silver acetate (250 mg, 1.5 mmol) in toluene (20 mL) over 15 h. Trituration with ether and filtration afforded the product (318 mg, 87%) as pale yellow needles, mp 131–133 °C. Found: C, 65.30; H, 4.90; N, 7.80. C₂₀H₁₈N₂O₅ requires: C, 65.55; H, 4.95; N, 7.65%; δ (¹H, 300 MHz): 7.87–7.83 (m, 4H, ArH), 7.54–7.47 (m, 3H, ArH), 7.43 (d, 1H, J 1.9 Hz, furyl-H'), 6.42 (dd, 1H, J 1.9 and 3.4 Hz, furyl-H'), 6.34 (d, 1H, J 3.4 Hz, furyl-H'), 5.46 (dd, 1H, J 6.0 and 2.6 Hz, 4-H), 5.05 (br s, 1H, 5-H), 4.38 (dd, 1H, J 6.8 and 2.6 Hz, 3-H), 4.29 (br d, 1H, J 6.0 Hz, 2-H), 3.90 (s, 3H, OMe) and 3.48 (br s, 1H, NH); δ (¹³C, CDCl₃+2 drops DMSO-*d*₆): 171.4 (CO), 150.7 (furan C_{2'}), 143.0 (furan C_{5'}), 133.1, 133.0 (C_q), 128.2, 128.1, 127.6 (ArCH), 126.5 (2×ArCH), 125.6, 124.5 (ArCH), 110.8, 107.9 (furan C_{3'}, C_{4'}), 93.9 (C₄), 67.1 (C₂), 64.3 (C₃), 52.7 (C₅) and 48.2 (OCH₃); ν_{\max} (KBr): 3302, 1743, 1541, 1436, 1127, 863, 812 and 747 cm⁻¹; m/z (ES⁺): 390 (M⁺+1+Na), 389 (M⁺+Na, 100), 367 (M⁺+1); m/z (% FAB): 367 (M⁺+1, 100), 233 (55).

7.2.14. Methyl 3-(2-furyl)-2-methyl-5-(2-naphthyl)-4-nitro-prolinate (**9n**)

Obtained from imine **6b** (241 mg, 1 mmol), *E*-nitrostyrene **7d** (139 mg, 1 mmol), triethylamine (0.21 mL, 1.5 mmol) and silver acetate (250 mg, 1.5 mmol) in toluene (20 mL) over 18 h. Trituration with ether and filtration afforded the product (304 mg, 80%) as a colourless solid, mp 110–112 °C. Found: C, 66.20; H, 5.25; N, 7.35. C₂₁H₂₀N₂O₅ requires: C, 66.30; H, 5.30; N, 7.35%; δ (¹H, 250 MHz): 7.87–7.80 (m, 4H, ArH), 7.52–7.41 (m, 4H, ArH), 6.39 (dd, 1H, J 2.0 and 3.2 Hz, furyl-H), 6.31 (d, 1H, J 3.2 Hz, furyl-H), 5.69 (dd, 1H, J 4.5 and 6.8 Hz, 4-H), 5.28 (dd, 1H, J 6.8 and 10.1 Hz, 5-H), 4.64 (d, 1H, J 4.5 Hz, 3-H), 3.92 (s, 3H, OMe), 3.54 (d, 1H, J 10.1 Hz, NH) and 1.29 (s, 3H, CH₃); δ (¹³C): 175.0 (CO), 150.1 (furan C_{2'}), 143.1 (furan C_{5'}), 133.8, 133.5 (C_q), 128.9, 128.6, 128.1, 126.9, 126.8, 126.4, 124.8 (ArCH), 111.2, 109.7 (furan C_{3'}, C_{4'}), 94.2 (C₄), 69.9 (C₂), 65.8 (C₃), 53.5 (C₅), 51.5 (OCH₃) and 22.5 (CH₃); ν_{\max} (KBr): 3361, 2998, 2949, 1734, 1552, 1436, 1148, 1014, 863, 772 and 752 cm⁻¹; m/z (%): 379 (M⁺-1, 10), 363 (25), 333 (40); m/z (ES): 404 (M⁺+1+Na), 403 (M⁺+Na), 381 (M⁺+1, 100).



NOE data for **9n**:

Irradiated proton	% Enhancement				
	H-3	H-4	H-5	Furyl	Naph-
H-3	—	2.9	—	5.5	—
H-4	4.5	—	7.4	2.0	—
H-5	—	13.5	—	6.2	6.7
CH ₃	1.5	0.8	2.1	—	—

7.2.15. Methyl 2-benzyl-3-(2-furyl)-5-(2-naphthyl)-4-nitro-prolinate (**9o**)

Obtained from imine **6c** (377 mg, 1 mmol), *E*-nitrostyrene **7d** (139 mg, 1 mmol), triethylamine (0.21 mL, 1.5 mmol) and silver acetate (250 mg, 1.5 mmol) in toluene (20 mL) over 16 h. Trituration with ether and filtration afforded the product (355 mg, 78%) as a pale orange amorphous solid, mp 151–154 °C. Found: C, 70.80; H, 5.30; N, 6.05. C₂₇H₂₄N₂O₅ requires: C, 71.05; H, 5.30; N, 6.15%; δ (¹H, 300 MHz): 7.92 (br s, 1H, ArH), 7.87–7.79 (m, 4H, ArH), 7.53–7.47 (m, 4H, ArH), 7.25–7.14 (m, 5H, ArH), 6.48–6.44 (m, 2H, furyl-H'), 5.63 (dd, 1H, J 3.8 and 6.4 Hz, 4-H), 5.34 (br t, 1H, J 7.7 Hz, 5-H), 4.55 (d, 1H, J 3.8 Hz, 3-H), 3.79 (s, 3H, OMe), 3.48 (br d, 1H, J 9.4 Hz, NH), 2.78 (AB, d, J 13.6 Hz, 1H, CHH) and 2.63 (AB, d, J 13.6 Hz, 1H, CHH); δ (¹³C): 173.9 (CO), 149.9 (furan C_{2'}), 136.8, 133.8, 133.6, 132.7 (C_q), 130.4 (2×ArCH), 128.6 (ArCH), 128.5 (2×ArCH), 128.1, 127.4, 126.9, 126.8, 126.4, 124.9 (ArCH), 111.3, 110.5 (furan C_{3'}, C_{4'}), 94.4 (C₄), 74.4 (C₂), 66.1 (C₃), 53.0 (C₅), 52.3 (OCH₃) and 40.8 (CH₂); ν_{\max} (film): 3328, 3122, 3056, 2951, 1740, 1602, 1542, 1455, 1429, 1195, 900, 868, 750 and 701 cm⁻¹; m/z (ES⁺): 457 (M⁺+1, 100).

7.2.16. Methyl 5-(1,1'-biphenyl-4-yl)-3-(2-furyl)-4-nitro-prolinate (**9p**)

Obtained from imine **6d** (253 mg, 1 mmol), *E*-nitrostyrene **7d** (139 mg, 1 mmol), triethylamine (0.21 mL, 1.5 mmol) and silver acetate (250 mg, 1.5 mmol) in toluene (20 mL) over 22 h. Purification by flash chromatography eluting with 19:1 v/v dichloromethane/hexane afforded the product (384 mg, 98%) as a colourless powder, mp 144–148 °C. Found: C, 67.30; H, 5.15; N, 7.20. C₂₂H₂₀N₂O₅ requires: C, 67.35; H, 5.15; N, 7.15%. δ (¹H, 250 MHz): 7.61–7.51 (m, 4H, ArH), 7.48–7.30 (m, 6H, ArCH), 6.39 (dd, 1H, J 1.9 and 3.6 Hz, furyl-H'), 6.31 (dd, 1H, J 0.5 and 3.6 Hz, furyl-H), 5.38 (dd, 1H, J 2.6 and 6.2 Hz, 4-H), 4.91 (dd, 1H, J 6.4 and 11.4 Hz, 5-H), 4.33 (dd, 1H, J 2.6 and 7.0 Hz, 3-H), 4.25 (dd, 1H, J 7.0 and 9.3 Hz, 2-H), 3.86 (s, 3H, OMe) and 3.37 (dd, 1H, J 9.3 and 11.4 Hz, NH); δ (¹³C, 250 MHz): 171.8 (CO), 151.2 (furyl C_{2'}), 143.4 (furyl C_{5'}), 142.0, 140.7, 133.3 (C_q), 129.2 (2×ArCH), 128.0 (ArCH), 127.9, 127.5, 127.3 (2×ArCH), 111.2, 108.4 (furyl C_{3'}+C_{4'}), 94.4 (C₄), 67.9 (C₂), 65.2 (C₃), 53.3 (C₅) and 49.3 (OCH₃); ν_{\max} (NaCl): 3375, 3030, 2952, 1742, 1551, 1437, 1214, 1008, 840, 766 and 699 cm⁻¹; m/z (%): 393 (M⁺+1, 100).

7.2.17. Methyl 5-(2-naphthyl)-4-nitro-3-thien-2-yl-prolinate (*endo*-**9q** and *exo*-**10q**)


Obtained from imine **6a** (227 mg, 1 mmol), *E*-nitrostyrene **7e** (155 mg, 1 mmol), triethylamine (0.21 mL, 1.5 mmol) and silver acetate (250 mg, 1.5 mmol) in toluene (20 mL) over 16 h. Trituration with ether and filtration afforded the product (343 mg, 90%; 3:1 mixture of *endo*-**9q** and *exo*-**10q**) as colourless plates, mp 124–130 °C. Found: C, 62.70; H, 4.80; N, 7.30; S, 8.40. C₂₀H₁₈N₂O₄S requires C, 62.80; H, 4.75; N, 7.30; S, 8.40%; NMR for both isomers were assigned from the 3:1 mixture.

δ_A (^1H , 300 MHz) for *endo*-**9q**: 7.85–7.80 (m, 4H, ArH), 7.60–7.55 (m, 4H, ArH), 7.03 (m, 2H, thienyl-H), 5.38 (dd, 1H, *J* 3.1 and 6.2 Hz, 4-H), 5.06 (d, 1H, *J* 6.2 Hz, 5-H), 4.59 (dd, 1H, *J* 3.1 and 7.1 Hz, 3-H), 4.26 (d, 1H, *J* 7.1 Hz, 2-H) and 3.88 (s, 3H, OMe); δ_A (^{13}C): 171.7 (CO), 141.6, 133.7, 133.5, 131.7 (C_q), 129.0, 128.6, 128.1, 128.0, 127.0, 126.9, 126.3, 126.1, 125.8, 124.5, (ArCH), 97.2 (C_4), 68.5 (C_2), 67.8 (C_3), 53.3 (C_5) and 50.9 (OCH₃).

δ_B (^1H , 300 MHz) for *exo*-**10q**: 8.06–7.84 (m, 4H, ArH), 7.69–7.48 (m, 3H, ArH), 7.23 (dd, 1H, *J* 1.6 and 4.9 Hz, thienyl-H'), 6.97 (m, 2H, thienyl-H), 5.24 (dd, 1H, *J* 6.5 and 7.6 Hz, 4-H), 4.87 (d, 1H, *J* 7.6 Hz, 5-H), 4.69 (dd, 1H, *J* 6.5 and 8.1 Hz, 3-H), 4.55 (d, 1H, *J* 8.1 Hz, 2-H) and 3.50 (s, 3H, OMe); δ_B (^{13}C): 171.6 (CO), 138.3, 135.3, 133.8 (C_q), 129.6, 128.2, 127.4, 126.8, 124.5, (ArCH), 96.7 (C_4), 68.2 (C_2), 64.9 (C_3), 52.6 (C_5) and 49.4 (OCH₃); ν_{max} (KBr): 3365, 3322, 2950, 1740, 1546, 1436, 1203, 832, 751 and 709 cm^{-1} ; *m/z* (% FAB): 383 (M^+ , 100); *m/z* (ES^+): 406 (M^++1+Na , 22), 405 (M^++Na , 100), 383 (M^++1 , 48).

7.2.18. Methyl 2-methyl-5-(2-naphthyl)-4-nitro-3-thien-2-yl-prolinate (**9r**)

Obtained from imine **6b** (241 mg, 1 mmol), *E*-nitrostyrene **7e** (155 mg, 1 mmol), triethylamine (0.21 mL, 1.5 mmol) and silver oxide (30 mg, 0.13 mmol) in toluene (20 mL) over 16 h. The crude material was washed with ether and filtered to afford the product (360 mg, 91%) as pale brown prisms, mp 156–158 °C. Found: C, 63.50; H, 5.00; N, 7.10; S, 8.20. $\text{C}_{21}\text{H}_{20}\text{N}_2\text{O}_4\text{S}$ requires: C, 63.60; H, 5.10; N, 7.05; S, 8.10%; δ (^1H , 250 MHz): 7.88–7.80 (m, 4H, ArH), 7.53–7.45 (m, 3H, ArH), 7.29–7.27 (m, 1H, thienyl-H), 7.02 (m, 2H, thienyl-H), 5.68 (t, 1H, *J* 7.0 Hz, 4-H), 5.24 (t, 1H, *J* 9.0 Hz, 5-H), 4.93 (d, 1H, *J* 6.8 Hz, 3-H), 3.95 (s, 3H, OMe), 3.35 (d, 1H, *J* 9.4 Hz NH) and 1.34 (s, 3H, CH₃); δ (^{13}C): 174.7 (CO), 138.2, 133.8, 133.5, 133.2 (C_q), 128.8, 128.6, 128.1, 127.5, 127.1, 126.9, 126.8, 126.7, 125.7, 124.9, (ArCH), 96.3 (C_4), 68.8 (C_2), 64.4 (C_3), 53.4 (C_5), 52.3 (OCH₃) and 22.2 (CH₃); ν_{max} (KBr): 3355, 2997, 2947, 1747, 1553, 1435, 1147, 822, 752 and 713 cm^{-1} ; *m/z* (% FAB): 397 (M^++1 , 85); *m/z* (ES^+): 420 (M^++1+Na), 419 (M^++Na), 397 (M^++1 , 71).



NOE data for **9r**:

Irradiated proton	% Enhancement				
	H-3	H-4	H-5	Thiophe-	Naph-
H-3	—	1.9	—	3.0	1.5, 1.3
H-4	2.5	—	7.8	4.5	—
H-5	—	9.8	—	0.8	4.6, 4.7

7.2.19. Methyl 2-benzyl-5-(2-naphthyl)-4-nitro-3-thien-2-yl-prolinate (**9s**)

Obtained from imine **6c** (317 mg, 1 mmol), *E*-nitrostyrene **7e** (155 mg, 1 mmol), triethylamine (0.21 mL, 1.5 mmol) and silver oxide (30 mg, 0.13 mmol) in toluene (20 mL) over 17 h. Purification was achieved by triturating the residue with ether and filtration to afford the product (330 mg, 70%) as a pale brown amorphous solid, mp 158–161 °C. Found: C, 68.35; H, 5.15; N, 6.10; S, 7.00. $\text{C}_{27}\text{H}_{24}\text{N}_2\text{O}_4\text{S}$ requires: C, 68.65; H, 5.10; N, 5.95; S, 6.80%; δ (^1H , 250 MHz): 7.93 (br s, 1H, ArH), 7.87–7.00 (m, 14H, ArH), 5.72 (dd, 1H, *J* 5.5 and 7.3 Hz, 4-H), 5.38 (br s, 1H, 5-H), 4.87 (d, 1H, *J* 5.5 Hz, 3-H), 3.81 (s, 3H, OMe), 3.39 (br s, 1H, NH) and 2.83 (s, 2H, CH₂); δ (^{13}C): 173.9 (CO), 137.9, 136.6, 133.8, 133.5, 133.1 (C_q), 130.4 (2 \times ArCH), 128.9 (ArCH), 128.6 (3 \times ArCH), 128.1, 128.0, 127.6, 127.5, 127.0, 126.9, 126.7, 126.0, 124.9 (ArCH), 97.1 (C_4), 73.1 (C_2), 64.9 (C_3), 53.4 (C_5), 53.0 (OCH₃) and 40.9

(CH₂); ν_{max} (KBr): 3330, 3118, 3094, 3055, 2948, 1743, 1543, 1453, 1428, 1194, 954, 902, 867, 749 and 702 cm^{-1} ; *m/z* (ES^+): 496 (M^++1+Na), 495 (M^++Na), 473 (M^++1 , 100); (ES^-): 471 (M^+-1 , 100); *m/z* (FAB⁺): 495 (M^++Na , 10), 473 (M^++1 , 100).

7.2.20. Methyl 5-(1,1'-biphenyl-4-yl)-4-nitro-3-thien-2-yl-prolinate (**9t**)

Obtained from imine **6d** (253 mg, 1 mmol), *E*-nitrostyrene **7e** (155 mg, 1 mmol), triethylamine (0.21 mL, 1.5 mmol) and silver acetate (250 mg, 1.5 mmol) in toluene (20 mL) over 16 h. Purification was achieved by dissolving the residue in toluene and adding ether dropwise, which afforded the product (285 mg, 70%) as colourless needles, mp 162–164 °C. Found: C, 64.65; H, 5.05; N, 6.85; S, 7.85. $\text{C}_{22}\text{H}_{20}\text{N}_2\text{O}_4\text{S}$ requires: C, 64.70; H, 4.95; N, 6.85; S, 7.85%; δ (^1H , 300 MHz): 7.60–7.48 (m, 5H, ArH), 7.43–7.24 (m, 5H, ArH and thienyl-H), 6.31 (dd, 1H, *J* 2.3 and 3.0 Hz, thienyl-H), 6.23 (d, 1H, *J* 3.0 Hz, thienyl-H), 5.30 (dd, 1H, *J* 3.0 and 6.0 Hz, 4-H), 4.83 (br d, 1H, *J* 6.0 Hz, 5-H), 4.25 (dd, 1H, *J* 3.0 and 6.8 Hz, 3-H), 4.15 (d, 1H, *J* 6.8 Hz, 2-H), and 3.79 (s, 3H, OMe); δ (^{13}C): 171.5 (CO), 151.0 (C_2), 143.2 (ArCH), 141.8, 140.5, 133.0 (C_q), 129.0 (2 \times ArCH), 127.7 (ArCH), 127.6 (2 \times ArCH), 127.3 (2 \times ArCH), 127.0 (2 \times ArCH), 111.0, 108.1 (thienyl CH), 94.2 (C_4), 67.6 (C_3), 65.0 (C_5), 53.0 (C_2) and 49.1 (OCH₃); ν_{max} (KBr): 3303, 3031, 2998, 2958, 1744, 1547, 1435, 1211, 1012, 830, 761 and 696 cm^{-1} ; *m/z* (ES^+): 431 (M^++Na), 393 (M^+-15 , 100), 375 (M^+-33).

7.2.21. Methyl 5-(2-naphthyl)-4-nitro-3-pyridin-3-yl-prolinate (**9u**)

Obtained from imine **6a** (227 mg, 1 mmol), *E*-nitrostyrene **7f** (150 mg, 1 mmol), triethylamine (0.21 mL, 1.5 mmol) and silver oxide (30 mg, 0.13 mmol) in toluene (20 mL) over 16 h. Purification was achieved by washing with ether and filtering off the product (150 mg, 40%) as pale yellow plates, mp 159–162 °C. Found: C, 66.95; H, 5.20; N, 11.30. $\text{C}_{21}\text{H}_{19}\text{N}_3\text{O}_4$ requires: C, 66.85; H, 5.05; N, 11.15%; δ (^1H , 300 MHz, CDCl_3+2 drops DMSO-*d*₆): 8.39 (br d, 1H, *J* 1.9 Hz, pyridyl-H), 8.34 (dd, 1H, *J* 1.9 and 4.7 Hz, pyridyl-H), 7.66 (br s, 1H, ArH), 7.62–7.56 (m, 3H, ArH), 7.52 (dt, 1H, *J* 1.9 and 7.9 Hz, pyridyl-H), 7.27–7.23 (m, 3H, ArH), 7.13 (dd, 1H, *J* 4.7 and 7.9 Hz, pyridyl-H), 5.28 (dd, 1H, *J* 4.7 and 7.3 Hz, 4-H), 4.94 (dd, 1H, *J* 7.3 and 9.4 Hz, 5-H), 4.06 (dd, 2H, *J* 4.7 and 8.3 Hz, 3-H), 3.93 (t, 1H, *J* 8.3 Hz, 2-H), 3.57 (s, 3H, OMe) and 3.29 (br t, 1H, *J* 9.4 Hz, NH); δ (^{13}C , CDCl_3+2 drops DMSO-*d*₆): 171.6 (CO), 149.8, 149.6 (pyridyl C_2 , C_6), 135.5 (pyridyl CH), 134.3, 133.5, 133.3 (C_q), 128.7, 128.4, 128.0 (ArCH), 126.8 (2 \times ArCH), 126.2, 124.7, 124.3, (ArCH), 96.4 (C_4), 67.6 (C_2), 67.2 (C_3), 53.1, (C_5) and 52.4 (OCH₃); ν_{max} (KBr): 3276, 3024, 2959, 1746, 1544, 1432, 1213, 832, 750 and 719 cm^{-1} ; *m/z* (% FAB): 378 (M^++1 , 80); *m/z* (ES^+): 401 (M^++1+Na), 400 (M^++Na), 378 (M^++1 , 100); (ES^-): 377 (M^+), 376 (M^+-1 , 100).

7.2.22. Methyl 2-methyl-5-(2-naphthyl)-4-nitro-3-pyridin-3-yl-prolinate (**9v**)


Obtained from imine **6b** (241 mg, 1 mmol), *E*-nitrostyrene **7f** (150 mg, 1 mmol), triethylamine (0.21 mL, 1.5 mmol) and silver acetate (250 mg, 1.5 mmol) in toluene (20 mL) over 18 h. Purification was achieved using a SPE-Anachem SI Mega Bond-Elut (20 g). Eluting with 100% hexane to 100% ethyl acetate gradient elution afforded the product (305 mg, 78%) as a colourless needles, mp 132–133 °C. Found: C, 67.50; H, 5.35; N, 10.55. $\text{C}_{22}\text{H}_{21}\text{N}_3\text{O}_4$ requires: C, 67.50; H, 5.40; N, 10.75%; δ (^1H , 300 MHz): 8.63 (br s, 1H, pyridyl-H), 8.61 (dd, 1H, *J* 1.7 and 4.5 Hz, pyridyl-H), 7.92 (br s, 1H, ArH), 7.86 (m, 3H, ArH), 7.68 (dt, 1H, *J* 1.7 and 7.9 Hz, pyridyl-H), 7.51 (m, 3H, ArH), 7.38 (dd, 1H, *J* 4.5 and 7.9 Hz, ArH), 5.75 (dd, 1H, *J* 6.6 and 7.3 Hz, 4-H), 5.28 (d, 1H, *J* 7.3 Hz, 5-H), 4.64 (d, 1H, *J* 6.6 Hz, 3-H), 3.93 (s, 3H, OMe), 3.50 (br s, 1H, NH) and 1.29 (s, 3H, CH₃); δ (^{13}C): 174.6 (CO), 150.4, 149.9 (pyridyl C_2 , C_6), 136.4 (ArCH), 133.8, 133.5, 132.9, 131.8 (C_q), 128.9, 128.6, 128.1, 126.93, 126.86, 126.7, 124.8,

123.9 (ArCH), 95.2 (C₄), 68.8 (C₂), 65.1 (C₃), 54.6 (C₅), 53.5 (OCH₃) and 22.8 (CH₃); ν_{\max} (KBr): 3367, 3322, 3024, 2947, 1757, 1741, 1547, 1430, 1136, 819, 757 and 715 cm⁻¹; m/z (ES): 414 (M⁺⁺+Na), 393 (M⁺⁺+2), 392 (M⁺⁺+1, 100); (ES⁻): 392, 391 (M⁺), 390 (M⁺-1, 100).

7.2.23. 3-Nitro-2,4-diphenyl-7-oxa-1-azaspiro[4.4]nonan-6-one (14a and 15a)

Obtained from imine **12a** (200 mg, 1.05 mmol), *E*-nitrostyrene (0.16 g, 1.05 mmol), triethylamine (0.16 mL, 1.55 mmol) and silver acetate (0.26 g, 1.6 mmol) in acetonitrile (10 mL) over 4 h. Purification by flash chromatography eluting with 4:1 v/v ether/hexane afforded first **15a** (70 mg, 20%), followed by **14a** (0.19 g, 54%) as colourless solids.


Cycloadduct 14a. Crystallised from dichloromethane/hexane as colourless plates, mp 144–146 °C. Found: C, 67.20; H, 5.40; N, 8.10. C₁₉H₁₈O₄N₂ requires: C, 67.40; H, 5.40; N, 8.30%; δ (¹H, 500 MHz): 7.42–7.26 (m, 10H, Ar-H), 5.79 (t, 1H, *J* 8.0 Hz, 3-H), 4.92 (dd, 1H, *J* 8.0 and 10.9 Hz, 2-H), 4.65 (d, 1H, *J* 8.0 Hz, 4-H), 4.18 (ddd, 1H, *J* 5.3, 8.0 and 8.9 Hz, 8-CH₂), 3.32 (dd, 1H, *J* 7.3 and 8.9 Hz, 8-CH₂), 3.19 (d, 1H, *J* 10.9 Hz, NH) and 2.28–2.18 (m, 2H, 9-CH₂); ν_{\max} (film): 1768, 1552, 1497, 1456, 1370, 1219, 1181, 1146, 1125 and 1053 cm⁻¹; m/z (%): 339 (M⁺+1, 0.4), 328 (2.2), 248 (54), 247 (53), 232 (86), 189 (43), 149 (60), 77 (92) and 57 (100).



NOE data for 14a:

Irradiated proton	% Enhancement					
	H-4	H-3	H-2	NH	8-CH ₂	ArH
H-4	—	—	—	2.0	—	7.3
H-3	1.0	—	6.8	—	—	8.5
H-2	—	6.7	—	1.0	3.8	5.6

Cycloadduct 15a. Crystallised from dichloromethane/hexane as colourless plates, mp 174–176 °C. Found: C, 67.35; H, 5.50; N, 8.30. C₁₉H₁₈O₄N₂ requires: C, 67.40; H, 5.40; N, 8.30%; δ (¹H, 500 MHz): 7.65 (d, 2H, *J* 7.4 Hz, Ar-H), 7.41–7.26 (m, 8H, Ar-H), 5.76 (t, 1H, *J* 8.3 Hz, 3-H), 5.28 (d, 1H, *J* 8.3 Hz, 2-H), 4.28 (ddd, 1H, *J* 4.2, 6.8 and 9.3 Hz, 8-CH₂), 4.12–4.08 (m, 2H, 8-CH₂ and 4-H), 2.44 (br, 1H, NH), 2.36 (dt, 1H, *J* 6.8 and 13.6 Hz, 9-CH₂) and 2.27 (dt, 1H, *J* 6.8 and 10.3 Hz, 9-CH₂); ν_{\max} (film): 1762, 1547, 1496, 1456, 1372, 1219, 1182 and 1022 cm⁻¹; m/z (%): 339 (M⁺+1, 0.3), 292 (26), 248 (66), 232 (88), 193 (100) and 115 (89).




NOE data for 15a:

Irradiated proton	% Enhancement			
	H-4	H-3	H-2	ArH
H-4	—	4.7	—	4.2
H-3	8.5	—	—	4.8
H-2	—	1.6	—	15.0

7.2.24. 3-Nitro-4-phenyl-2-pyridin-3-yl-7-oxa-1-azaspiro[4.4]nonan-6-one (14b)

Obtained from imine **12b** (200 mg, 1.05 mmol), *E*-nitrostyrene (0.16 g, 1.05 mmol), triethylamine (0.16 mL, 1.55 mmol) and silver

acetate (0.26 g, 1.6 mmol) in acetonitrile (10 mL) over 4 h. Purification by flash chromatography eluting with ethyl acetate afforded the cycloadduct **14b** (144 mg, 40%) as a colourless solid together with small amount of epimerised cycloadduct. Product **14b** crystallised from dichloromethane/hexane as colourless needles, mp 170–172 °C. Found: C, 63.45; H, 5.00; N, 12.55. C₁₈H₁₇O₄N₃ requires: C, 63.71; H, 5.05; N, 12.38%; δ (¹H, 250 MHz): 8.63 (m, 2H, pyridyl-H), 7.9 (m, 1H, pyridyl-H), 7.45–7.26 (m, 6H, pyridyl-H and Ar-H), 5.82 (t, 1H, *J* 8.3 Hz, 3-H), 4.96 (dd, 1H, *J* 8.3 and 10.2 Hz, 2-H), 4.65 (d, 1H, *J* 8.3 Hz, 4-H), 4.17 (dd, 1H, *J* 5.0 and 8.6 Hz, 8-CH₂), 3.28 (dd, 1H, *J* 7.4 and 8.6 Hz, 8-CH₂), 3.08 (d, 1H, *J* 10.2 Hz, NH) and 2.36–2.15 (m, 2H, 9-CH₂); ν_{\max} (film): 1769, 1552, 1372, 1218, 1183 and 1024 cm⁻¹; m/z (%): 340 (M⁺+1, 7), 293 (12), 249 (59), 233 (91), 194 (100) and 115 (21).



NOE data for 14b:

Irradiated proton	% Enhancement				
	H-4	H-3	H-2	NH	ArH
H-4	—	—	—	1.8	12.0
H-3	—	—	7.7	—	13.4
H-2	—	8.4	—	1.7	7.9

7.2.25. 3-Nitro-4-phenyl-2-*N*-sulphonylindol-3-yl-7-oxa-1-azaspiro[4.4]nonan-6-one (14c and 15c)

Obtained from imine **12c** (200 mg, 0.54 mmol), *E*-nitrostyrene (0.08 mg, 0.54 mmol), triethylamine (0.08 mL, 0.6 mmol) and silver acetate (0.14 g, 0.59 mmol) in acetonitrile (20 mL) over 24 h. Purification by flash chromatography eluting with 9:1 v/v ether/hexane afforded first **15c** (191 mg, 68%) followed by **14c** (42 mg, 15%).

Cycloadduct 14c. Crystallised from dichloromethane/hexane as colourless needles, mp 138–140 °C. Found (HRMS, M⁺+H): 518.1388. C₂₇H₂₃O₆N₃S requires: 518.1386; δ (¹H, 250 MHz): 7.97–7.24 (m, 10H, ArH), 5.83 (t, 1H, *J* 7.5 Hz, 3-H), 5.12 (dd, 1H, *J* 7.5 and 11.0 Hz, 2-H), 4.68 (d, 1H, *J* 7.5 Hz, 4-H), 4.19 (ddd, 1H, *J* 5.9, 7.6 and 11.3 Hz, 8-CH₂), 3.36 (dd, 1H, *J* 7.2 and 11.3 Hz, 8-CH₂), 3.21 (d, 1H, *J* 11.0 Hz, NH) and 2.28–2.21 (m, 2H, 9-CH₂); ν_{\max} (film): 1769, 1552, 1448, 1368, 1216 and 1175 cm⁻¹; m/z (%): 517 (1.3), 471 (6), 427 (9), 368 (54), 285 (11), 271 (8), 227 (28) and 77 (100).

Cycloadduct 15c. Crystallised from dichloromethane/hexane as colourless plates, mp 157–159 °C. Found (HRMS, M⁺+H): 518.1390. C₂₇H₂₃O₆N₃S requires: 518.1386; δ (¹H, 250 MHz): 7.98–7.23 (m, 10H, ArH), 5.73 (t, 1H, *J* 6.4 Hz, 3-H), 5.47 (d, 1H, *J* 6.4 Hz, 2-H), 4.34 (m, 1H, 8-CH₂), 4.16–4.07 (m, 2H, 8-CH₂ and 4-H), 2.66 (br, 1H, NH) and 2.48–2.32 (m, 2H, 9-CH₂); ν_{\max} (film): 1766, 1549, 1448, 1371, 1175 and 1125 cm⁻¹; m/z (%): 517 (M⁺, 1.5), 427 (28), 368 (24), 329 (6), 285 (38), 230 (41) and 77 (100).

7.2.26. 2-Cyclohexyl-3-nitro-4-phenyl-7-oxa-1-azaspiro[4.4]nonan-6-one (14d)

Obtained from imine **12d** (1 g, 5.11 mmol), *E*-nitrostyrene (0.76 g, 5.11 mmol), triethylamine (0.8 mL, 5.62 mmol) and silver oxide (0.12 g, 0.5 mmol) in toluene (50 mL) over 1 h. Purification by flash chromatography eluting with 1:1 v/v ether/hexane afforded the product (1.32 g, 74%), which crystallised from dichloromethane/hexane as colourless plates, mp 159–161 °C. Found: C, 66.25; H, 7.15; N, 8.40. C₁₉H₂₄O₄N₂ requires: C, 66.25; H, 7.00; N, 8.15%; δ (¹H, 250 MHz): 7.57–7.12 (m, 5H, Ar-H), 5.51 (dd, 1H, *J* 4.7 and 5.9 Hz, 3-H), 4.40 (d, 1H, *J* 4.7 Hz, 4-H), 4.16 (dt, 1H, *J* 6.8 and 8.7 Hz, 8-CH₂),

3.45 (m, 1H, 8-CH₂), 3.19 (m, 1H, 2-H), 2.79 (d, 1H, *J* 14.1 Hz, NH), 2.05–1.99 (m, 3H, 9-CH₂ and cyclohexyl-H) and 1.89–1.21 (m, 10H, cyclohexyl-H); ν_{\max} (film): 2925, 2853, 1769, 1546, 1452, 1369, 1218 and 1175 cm⁻¹; *m/z* (%): 345 (M⁺+1, 0.7), 298 (16), 254 (76), 199 (91), 170 (73), 156 (77), 143 (40) and 117 (100).

7.2.27. 2-Cyclohex-3-en-1-yl-3-nitro-4-phenyl-7-oxa-1-azaspiro[4.4]nonan-6-one (**14e**)

Obtained from imine **12e** (400 mg, 2.06 mmol), *E*-nitrostyrene (0.31 g, 2.06 mmol), triethylamine (0.3 mL, 2.26 mmol) and silver oxide (47 mg, 0.2 mmol) in toluene (30 mL) over 1 h. Purification by flash chromatography eluting with ether afforded the product (0.36 g, 51%) as a 1:1 mixture of diastereomers, which crystallised from dichloromethane/hexane as colourless plates, mp 134–142 °C. Found: C, 66.45; H, 6.50; N, 8.00. C₁₉H₂₂O₄N₂ requires: C, 66.65; H, 6.50; N, 8.20%; δ (¹H, 250 MHz): 7.38–7.14 (m, 5H, Ar-H), 5.68–5.48 (m, 3H, olefinic-H and 3-H), 4.44 and 4.43 (d, 1H, *J* 4.5 Hz, 4-H), 4.16 (m, 1H, 8-CH₂), 3.49–3.30 (m, 2H, 8-CH₂ and 2-H), 2.86 and 2.80 (d, 1H, *J* 6.4 Hz, NH) and 2.27–1.59 (m, 9H, 9-CH₂ and cyclohexenyl-H); ν_{\max} (film): 2918, 1769, 1733, 1653, 1546, 1506, 1496, 1437, 1317 and 1271 cm⁻¹; *m/z* (%): 342 (M⁺, 0.4), 325 (0.6), 252 (90), 215 (23), 197 (64), 170 (71), 156 (93), 143 (73) and 117 (100).

7.2.28. 2-(2,6-Dimethyl-5-heptenyl)-3-nitro-4-phenyl-7-oxa-1-azaspiro[4.4]nonan-6-one (**14f**)

Obtained from imine **12f** (700 mg, 2.95 mmol), *E*-nitrostyrene (0.44 g, 2.95 mmol), triethylamine (0.5 mL, 3.24 mmol) and silver oxide (68 mg, 0.3 mmol) in toluene (30 mL) over 4 h. Purification by flash chromatography eluting with 1:1 v/v ether/hexane afforded the product (0.44 g, 42%) as a pale yellow oil, which comprised a 1:1 mixture of diastereomers. Found: C, 68.50; H, 7.90; N, 7.10. C₁₉H₂₂O₄N₂ requires: C, 68.40; H, 7.80; N, 7.25%; δ (¹H, 250 MHz): 7.41–7.16 (m, 5H, Ar-H), 5.48 (m, 1H, 3-H), 5.06 (m, 1H, olefinic-H), 4.49 (m, 1H, 4-H), 4.16 (m, 1H, 8-CH₂), 3.65 (m, 1H, 2-H), 3.35 (m, 1H, 8-CH₂), 2.50 (br, 1H, NH), 2.12–1.91 (m, 4H, 9-CH₂ and citronellyl-H), 1.69 and 1.60 (2×s, 2×3H, Me₂C=C) and 1.58–1.14 (m, 3H, citronellyl-CH₃); ν_{\max} (film): 2954, 2916, 1770, 1549, 1373, 1219, 1180 and 1023 cm⁻¹; *m/z* (%): 386 (M⁺, 1.2), 340 (16), 312 (21), 296 (100), 282 (20), 256 (6), 241 (9), 210 (12), 184 (41), 170 (83) and 156 (96).

7.2.29. 2-(8,8-Dimethyl-1,2,3,4,5,6,7,8-octahydro-2-naphthalenyl)-3-nitro-4-phenyl-7-oxa-1-azaspiro[4.4]nonan-6-one (**14g**)

Obtained from imine **12g** (1.0 g, 3.6 mmol), *E*-nitrostyrene (0.53 g, 3.6 mmol), triethylamine (0.55 mL, 3.9 mmol) and silver oxide (0.08 g, 0.36 mmol) in toluene (40 mL) over 3 h. Purification by flash chromatography eluting with 1:1 v/v ether/hexane afforded the product (0.89 g, 58%) as a 1:1 mixture of diastereomers, which crystallised from dichloromethane/hexane as colourless plates, mp 165–172 °C. Found: C, 71.00; H, 7.65; N, 6.35. C₂₅H₃₂O₄N₂ requires: C, 70.75; H, 7.60; N, 6.60%; δ (¹H, 250 MHz): 7.38–7.35 (m, 3H, Ar-H), 7.16–7.14 (m, 2H, Ar-H), 5.53 (m, 1H, 3-H), 4.45 (m, 1H, 4-H), 4.18 and 3.46 (2×m, 2×1H, 8-CH₂), 3.43 (m, 1H, 2-H), 2.84 (br, 1H, NH), 2.06–1.43 (m, 15H, 9-CH₂ and aliphatic-H), 1.02 and 0.95 (2×s, 2×3H, CH₃); ν_{\max} (film): 2924, 1771, 1547, 1369, 1219, 1176 and 1023 cm⁻¹; *m/z* (%): 424 (M⁺, 1.5), 407 (5), 378 (10), 334 (25), 216 (62), 143 (80), 117 (80) and 91 (100).

7.2.30. 2-[3-(4-Methyl-3-pentenyl)-3-cyclohexen-1-yl]-3-nitro-4-phenyl-7-oxa-1-azaspiro[4.4]nonan-6-one (**14h**)

Obtained from imine **12h** (1.5 g, 5.4 mmol), *E*-nitrostyrene (0.81 g, 5.4 mmol), triethylamine (0.83 mL, 5.9 mmol) and silver oxide (0.12 g, 0.54 mmol) in toluene (40 mL) over 4 h. Purification by flash chromatography eluting with 1:1 v/v ether/hexane afforded the product (1.96 g, 85%) as a 1:1 mixture of diastereomers, which crystallised from dichloromethane/hexane as colourless

plates, mp 94–102 °C. Found: C, 70.75; H, 7.60; N, 6.60. C₂₅H₃₂O₄N₂ requires: C, 70.75; H, 7.60; N, 6.60%; δ (¹H, 250 MHz): 7.38–7.33 (m, 3H, Ar-H), 7.17–7.14 (m, 2H, Ar-H), 5.58 and 5.51 (dd, 1H, *J* 4.5 and 5.9 Hz, 3-H), 5.36 (br, 1H, olefinic-H), 4.45 and 4.42 (d, 1H, *J* 4.5 Hz, 4-H), 4.17 (ddd, 1H, *J* 1.9, 6.7 and 8.7 Hz, 8-CH₂), 3.44 (m, 1H, 8-CH₂), 3.34 (m, 1H, 2-H), 2.84 (br, 1H, NH), 2.25 (m, 1H, aliphatic-H), 2.06–1.98 (m, 11H, 9-CH₂ and aliphatic-H), 1.69 and 1.61 (2×s, 2×3H, 2×CH₃) and 1.43 (m, 1H, aliphatic-H); ν_{\max} (film): 2917, 1771, 1547, 1369, 1219, 1176, 1119 and 1023 cm⁻¹; *m/z* (%): 424 (M⁺, <1), 407 (3), 378 (5), 333 (3), 91 (34), 77 (16) and 69 (100).

7.2.31. 2-[2-(4-Isopropylphenyl)-1-methylethyl]-3-nitro-4-phenyl-7-oxa-1-azaspiro[4.4]nonan-6-one (**14i**)

A mixture of imine **12i** (1.0 g, 3.6 mmol), *E*-nitrostyrene (0.54 g, 3.6 mmol), triethylamine (0.56 mL, 4.0 mmol) and silver oxide (0.08 g, 0.36 mmol) in toluene (40 mL) was stirred for 5 h. Flash chromatography eluting with 1:1 v/v ether/hexane separated the 1:1 mixture of diastereomers (combined yield 1.11 g, 72%).

First eluting isomer. Crystallised from dichloromethane/hexane as colourless rods, mp 143–145 °C. Found: C, 71.15; H, 7.25; N, 6.45. C₂₅H₃₀O₄N₂ requires: C, 71.10; H, 7.15; N, 6.65%; δ (¹H, 250 MHz): 7.39–7.34 (m, 3H, Ar-H), 7.15–7.10 (m, 6H, Ar-H), 5.46 (dd, 1H, *J* 4.6 and 5.7 Hz, 3-H), 4.43 (d, 1H, *J* 4.6 Hz, 4-H), 4.25 (ddd, 1H, *J* 6.5, 7.5 and 8.7 Hz, 8-CH₂), 3.54 (ddd, 1H, *J* 5.8, 7.5 and 8.7 Hz, 8-CH₂), 3.14 (m, 1H, 2-H), 3.03–2.83 (m, 3H, NH and aliphatic-H), 2.59 (dd, 1H, *J* 8.1 and 14.5 Hz, aliphatic-CH₂), 2.09–1.92 (m, 3H, 9-CH₂ and aliphatic-H), 1.24 (d, 2×3H, *J* 6.9 Hz, 2×CH₃) and 0.97 (d, 3H, *J* 6.6 Hz, CH₃); ν_{\max} (film): 2969, 1772, 1548, 1457, 1370, 1220 and 1022 cm⁻¹; *m/z* (%): 422 (M⁺, <1), 407 (<1), 378 (13), 332 (47), 277 (9), 244 (10), 170 (57), 133 (100), 117 (51) and 91 (38).

Second eluting isomer. Crystallised from dichloromethane/hexane as colourless rods, mp 120–122 °C. Found: C, 70.95; H, 7.00; N, 6.70. C₂₅H₃₀O₄N₂ requires: C, 71.10; H, 7.15; N, 6.65%; δ (¹H, 250 MHz): 7.42–7.33 (m, 3H, Ar-H), 7.17–7.05 (m, 6H, Ar-H), 5.61 (dd, 1H, *J* 5.2 and 6.3 Hz, 3-H), 4.50 (d, 1H, *J* 5.2 Hz, 4-H), 4.18 (dt, 1H, *J* 6.8 and 8.8 Hz, 8-CH₂), 3.44 (dt, 1H, *J* 6.8 and 8.8 Hz, 8-CH₂), 3.31 (m, 1H, 2-H), 2.99–2.77 (m, 3H, NH and aliphatic-H), 2.34 (dd, 1H, *J* 9.8 and 13.2 Hz, aliphatic-CH₂), 2.06–2.01 (t, 2H, *J* 6.8 Hz, 9-CH₂), 1.90 (m, 1H, aliphatic-H), 1.24 (d, 2×3H, *J* 7.0 Hz, 2×CH₃) and 1.01 (d, 3H, *J* 6.6 Hz, CH₃); ν_{\max} (film): 2961, 1771, 1652, 1547, 1507, 1497, 1369 and 1219 cm⁻¹; *m/z* (%): 422 (M⁺, <1), 407 (1), 376 (9), 332 (61), 277 (12), 244 (15), 170 (56) and 133 (100).

7.2.32. 2-(2-Methyl-4-phenylbutyl)-3-nitro-4-phenyl-7-oxa-1-azaspiro[4.4]nonan-6-one (**14j**)

Obtained from imine **12j** (1.0 g, 3.85 mmol), *E*-nitrostyrene (0.57 g, 3.85 mmol), triethylamine (0.6 mL, 4.23 mmol) and silver oxide (0.089 g, 0.38 mmol) in toluene (40 mL) over 4 h. Purification by flash chromatography eluting with 1:1 v/v ether/hexane afforded the product (0.93 g, 59%) as a 1:1 mixture of diastereomers, which crystallised from dichloromethane/hexane as colourless plates, mp 75–83 °C. Found: C, 70.80; H, 6.70; N, 6.60. C₂₄H₂₈O₄N₂ requires: C, 70.60; H, 6.90; N, 6.85%; δ (¹H, 250 MHz): 7.38–7.14 (m, 10H, Ar-H), 5.44 (m, 1H, 3-H), 4.50 (m, 1H, 4-H), 4.13 (m, 1H, 8-CH₂), 3.63 (m, 1H, 2-H), 3.34 (m, 1H, 8-CH₂), 2.70–2.47 (m, 3H, NH and aliphatic-H), 2.09–1.98 (m, 2H, 9-CH₂), 1.73–1.39 (m, 5H, aliphatic-H) and 1.04 and 1.0 (d, 3H, *J* 6.4 Hz, CH₃); ν_{\max} (film): 2922, 1770, 1548, 1496, 1455, 1370, 1270 and 1177 cm⁻¹; *m/z* (%): 408 (M⁺, <1), 362 (6), 334 (7), 318 (70), 304 (10), 263 (8), 185 (14) and 91 (100).


7.3. N-Acetylation of cycloadducts^{8b}

Acetic anhydride (11 mol equiv, 0.46 mL, 0.5 g, 4.86 mmol) was added at 0 °C to a solution of cycloadducts *endo*-**9q** and *exo*-**10q** (170 mg, 0.44 mmol) in pyridine (3 mL). The mixture was stirred at room temperature for 3 h and then poured into ice water. The

products were extracted with dichloromethane and the organic layer washed sequentially with 5% aqueous HCl, saturated aqueous NaHCO₃ and brine, dried (MgSO₄), and concentrated in vacuo. The isomers were separated by column chromatography eluting with 3:2 v/v hexane/ethyl acetate.

7.3.1. Methyl *N*-acetyl-5-naphthalen-2-yl-4-nitro-3-thiophen-2-yl-pyrrolidine-2-carboxylate (**16a**)

The major isomer (255 mg, 40%) crystallised as colourless prisms from hexane/EtOAc, *R*_f 0.3, mp 203–205 °C. Found: C, 62.25; H, 4.90; N, 6.65; S, 7.70. C₂₂H₂₀N₂O₅S requires: C, 62.25; H, 4.75; N, 6.60; S, 7.55%; δ (¹H, 500 MHz, C₆D₆): 8.61 (s, 1H, 1'-H), 8.00 (dd, 1H, *J* 1.1 and 8.5 Hz, 3'-H), 7.98 (m, 1H, ArH), 7.83 (d, 1H, *J* 8.5 Hz, ArH), 7.74 (m, 1H, ArH), 7.35 (m, 2H, ArH), 7.06 (dd, 1H, *J* 1.1, 5.1 Hz, Ha), 6.99 (d, 1H, *J* 3.6 Hz, Hc), 6.72 (dd, 1H, *J* 3.6, 5.1 Hz, Hb), 6.12 (s, 1H, 5-H), 5.45 (d, 1H, *J* 6.0 Hz, 4-H), 5.28 (d, 1H, *J* 10.9 Hz, 2-H), 4.52 (dd, 1H, *J* 6.0, 10.9 Hz, 3-H), 3.44 (s, 3H, CO₂CH₃), and 1.78 (s, 3H, COCH₃); δ (¹³C): 171.9 (ester CO), 171.1 (amide CO), 134.9 (C_q), 133.8 (2×C_q), 132.8 (C_q), 130.3, 128.9, 128.2, 127.9, 127.6 (ArCH), 127.5, 126.8 (2×ArCH), 123.9 (ArCH), 96.3 (C₄), 66.8 (C₅), 64.2 (C₂), 53.4 (OCH₃), 45.1 (C₃), and 22.4 (CH₃); IR (DCM): 2952, 1746, 1663, 1556, 1437, 1367, 1207, 1178, 860, and 737 cm⁻¹; *m/z* (ES⁺): 425 (M⁺+1, 100).




NOE data for **16a**:

Irradiated proton	% Enhancement						
	H-4	COCH ₃	H-1'	H-3'	H-5	H-3	Hc
H-5	7.9	9.0	6.1	7.2	—	—	—
H-4	—	—	1.5	3.2	4.4	13.4	—
H-3	18.6	—	4.5	2.2	—	—	3.2
H-2	—	—	2.6	—	1.1	3.0	10.3

7.3.2. Methyl *N*-acetyl-5-naphthalen-2-yl-4-nitro-3-thiophen-2-yl-pyrrolidine-2-carboxylate (**16b**)

The minor isomer (166 mg, 26%) crystallised from hexane/EtOAc as colourless prisms, *R*_f 0.2, mp 212–214 °C. Found: C, 61.95; H, 4.90; N, 6.55; S, 7.60. C₂₂H₂₀N₂O₅S requires: C, 62.25; H, 4.75; N, 6.60; S, 7.55%; δ (¹H, 500 MHz): 7.97 (m, 3H, ArH), 7.87 (m, 2H, ArH), 7.55 (m, 2H, ArH), 7.29 (dd, 1H, *J* 1.0 and 5.0 Hz, Ha), 7.00 (d, 1H, *J* 3.5 Hz, Hc), 6.97 (dd, 1H, *J* 3.5 and 5.0 Hz, Hb), 5.67 (dd, 1H, *J* 8.5 and 11.6 Hz, 4-H), 5.49 (d, 1H, *J* 8.5 Hz, 5-H), 5.19 (d, 1H, *J* 9.4 Hz, 2-H), 4.67 (dd, 1H, *J* 9.4 and 11.6 Hz, 3-H), 3.54 (s, 3H, CO₂CH₃) and 1.68 (s, 3H, COCH₃); δ (¹³C): 171.3, 171.2 (CO), 135.2, 134.1, 133.6, 133.4 (C_q), 130.6, 128.6, 128.3, 127.7, 127.4 (ArCH), 127.3 (2×ArCH), 127.2, 126.9, 123.8 (ArCH), 95.2 (C₄), 67.5 (C₂), 64.3 (C₃), 52.9 (C₅), 45.6 (OCH₃) and 23.2 (CH₃); IR (DCM): 2951, 1742, 1663, 1558, 1437, 1369, 1215, 862, and 752 cm⁻¹; *m/z* (ES⁺): 448 (M⁺+1+Na, 30), 446 (M⁺+Na, 100).



NOE data for **16b**:

Irradiated proton	% Enhancement				
	H-5	H-4	H-1'	H-2	H-3
H-1'	11.3	4.46	1.03	—	—
H-5	5.6	—	5.28	5.54	2.02
H-4	—	6.47	—	—	14.2
H-3	—	—	14.3	—	—
H-2	—	3.66	—	—	—

7.3.3. Methyl *N*-acetyl-3-(1*H*-indol-3-yl)-5-naphthalen-2-yl-4-nitro-pyrrolidine-2-carboxylate (**17a**)

Prepared by the general method from *endo*-**9c**. Trituration with ether afforded the product as pale yellow needles (618 mg, 90%), mp 190–192 °C. Found: C, 68.25; H, 5.25; N, 9.30. C₂₆H₂₃N₃O₅ requires: C, 68.26; H, 5.07; N, 9.18%. δ (¹H, 250 MHz): 8.41 (s, 1H, indole NH), 8.27 (s, 1H, ArH), 7.90–7.65 (m, 4H, ArH), 7.60–7.40 (m, 3H, ArH), 7.30 (d, 1H, *J* 8.0 Hz, ArH), 7.20–7.05 (m, 3H, ArH), 5.72 (m, 2H, 5-H+4-H), 4.83 (d, 1H, *J* 10.0 Hz, 2-H), 3.78 (t, 1H, *J* 10.0 Hz, 3-H), 3.65 (s, 3H, CO₂CH₃) and 1.83 (s, 3H, CH₃); δ (¹³C): 171.9 (ester CO), 171.2 (amide CO), 137.0, 134.0, 133.6, 132.6 (C_q), 129.6, 128.9, 128.2, 127.8, 127.3, 127.1 (ArCH), 125.9 (C_q), 124.7, 123.4, 123.2, 120.7, 118.9, 112.3 (ArCH), 108.5 (C_q), 90.8 (C₄), 64.3 (C₅), 63.3 (C₂), 53.2 (OCH₃), 41.5 (C₃) and 22.6 (CH₃); IR (DCM): 3420, 3058, 2951, 1745, 1653, 1558, 1436, 1349, 1214, 1014, 867 and 744 cm⁻¹; *m/z* (ES⁺): 458 (M⁺+1, 100).

7.3.4. Methyl *N*-acetyl-3-[4-(acetyloxy)-3-methoxyphenyl]-5-biphenyl-4-yl-4-nitro-pyrrolidine-2-carboxylate (**17b**)

Prepared by the general method from *endo*-**9i**. Trituration with ether afforded the product as a colourless amorphous powder (707 mg, 93%), mp 206–208 °C. HRMS found: 533.1918C₂₉H₂₉N₂O₈ requires: 533.1924. Found: C, 65.70; H, 5.35; N, 5.05. C₂₉H₂₈N₂O₈ requires: C, 65.40; H, 5.30; N, 5.26%; δ (¹H, 500 MHz, CDCl₃+C₆D₆): 7.80 (d, 2H, *J* 8.3 Hz, ArH), 7.68 (dd, 2H, *J* 1.9 and 8.3 Hz, ArH), 7.57 (dd, 2H, *J* 1.2 and 8.4 Hz, ArH), 7.42 (dd, 2H, *J* 7.0 and 8.4 Hz, ArH), 7.33 (m, 1H, ArH), 6.94 (d, 1H, *J* 8.2 Hz, Hc), 6.79 (d, 1H, *J* 1.9 Hz, Ha), 6.72 (dd, 1H, *J* 1.9 and 8.2 Hz, Hb), 5.43 (s, 1H, 5-H), 5.22 (d, 1H, *J* 10.8 Hz, 2-H), 5.10 (dd, 1H, *J* 0.7 and 6.2 Hz, 4-H), 4.02 (dd, 1H, *J* 10.8 and 6.2 Hz, 3-H), 3.71 (s, 3H, CO₂CH₃), 3.70 (s, 3H, ArOCH₃), 2.20 (s, 3H, ester CH₃) and 1.89 (s, 3H, NCOCH₃); δ (¹³C, 125 MHz, CDCl₃+C₆D₆): 171.9 (—CO), 170.6 (amide CO), 168.5 (ester —OCO), 151.6, 142.2, 140.3, 140.0, 136.5, 129.9 (C_q), 129.0, 128.4 (2×ArCH), 127.9 (ArCH), 127.1, 127.0 (2×ArCH), 123.5, 120.1, 111.8 (vanillin ArCH), 96.3 (C₄), 66.4 (C₅), 62.2 (C₂), 55.9 (ArOCH₃), 52.9 (OCH₃), 48.7 (C₃), 21.9 (N-acetyl CH₃) and 20.5 (O-acetyl CH₃); IR (DCM) cm⁻¹ 3248, 3062, 3029, 2953, 1748, 1663, 1554, 1516, 1402, 1368, 1351, 1264, 1204, 1033, 1009 and 856. *m/z* (ES⁺): 556 (M⁺+1+Na, 36), 555 (M⁺+Na, 100).

7.4. General procedure for reduction of the NO₂ group

Zinc dust (135 mg, 2.06 mmol) was added to a stirred solution of nitro compound (52 mg, 0.12 mmol) in ethanol (10 mL). The mixture was then heated to 40–45 °C and concd HCl (0.2 mL) was added keeping the temperature in between 45 and 50 °C. The reaction mixture was then refluxed for 12 h, filtered and the filtrate evaporated in vacuo nearly to dryness. The residue was extracted with DCM and saturated NaHCO₃ solution was added until the pH was slightly basic and then extracted with more DCM. The combined DCM extracts were dried (MgSO₄), filtered and the filtrate evaporated under reduced pressure.

7.4.1. Methyl *N*-acetyl-4-amino-5-naphthalene-2-yl-3-thiophen-2-yl-pyrrolidine-2-carboxylate (**18a**)

Flash column chromatography eluting with ethyl acetate followed by 3:1 v/v methanol/hexane afforded the product as

colourless plates (347 mg, 88%), R_f 0.33, mp 81–83 °C. Found: C, 66.70; H, 5.70; N, 6.85; S, 8.00. $C_{22}H_{22}N_2O_3S$ requires C, 66.98; H, 5.62; N, 7.10; S, 8.13%. δ (1H , 250 MHz): 8.07 (s, 1H, ArH), 7.75–7.51 (m, 3H, ArH), 7.35–7.30 (m, 2H, ArH), 7.10–7.05 (m, 1H, ArH), 6.85–6.80 (m, 2H, ArH), 4.79 (d, 1H, J 7.4 Hz, 5-H), 4.66 (d, 1H, J 4.6 Hz, 2-H), 3.78 (dd, 1H, J 4.6, 7.4 Hz, 4-H), 3.63 (s, 3H, CO_2CH_3), 3.47 (t, 1H, J 4.6 Hz, 3-H), and 1.69 (s, 3H, CH_3). δ (^{13}C): 172.5, 171.8 (CO), 138.0, 137.6, 133.8, 133.4 (C_q), 129.5, 128.6, 128.1, 127.6, 127.1, 126.9, 126.8, 126.3, 125.6, 124.7 (ArCH), 70.7 (C_4), 64.3 (C_2), 63.8 (C_3), 53.0 (C_5), 46.4 (OCH_3), and 22.7 (CH_3). IR (DCM): 2950, 1743, 1653, 1559, 1436, 1406, 1351, 1201, 861, and 755 cm^{-1} . m/z (ES^+): 396 ($M^+ + 2$), 395 ($M^+ + 1$, 100).

7.4.2. Methyl *N*-acetyl-4-amino-5-naphthalene-2-yl-3-thiophen-2-yl-pyrrolidine-2-carboxylate (**18b**)

Trituration with ether afforded the product as a colourless amorphous powder (375 mg, 95%), mp 209–211 °C. HRMS found: $395.1429C_{22}H_{22}N_2O_3S$ requires: 395.1424. Found: C, 66.40; H, 5.75; N, 6.90. $C_{22}H_{22}N_2O_3S$ requires: C, 66.98; H, 5.62; N, 7.10%; δ (1H , 250 MHz): 8.07 (s, 1H, ArH), 7.75–7.51 (m, 3H, ArH), 7.35–7.30 (m, 2H, ArH), 7.10–7.05 (m, 1H, ArH), 6.85–6.80 (m, 2H, ArH), 4.79 (d, 1H, J 7.4 Hz, 5-H), 4.66 (d, 1H, J 4.6 Hz, 2-H), 3.78 (dd, 1H, J 4.6 and 7.4 Hz, 4-H), 3.63 (s, 3H, CO_2CH_3), 3.47 (t, 1H, J 4.6 Hz, 3-H) and 1.69 (s, 3H, CH_3); δ (^{13}C): 172.5, 171.8 (CO), 138.0, 137.6, 133.8, 133.4 (C_q), 129.5, 128.6, 128.1, 127.6, 127.1, 126.9, 126.8, 126.3, 125.6, 124.7 (ArCH), 70.7 (C_4), 64.3 (C_2), 63.8 (C_3), 53.0 (C_5), 46.4 (OCH_3) and 22.7 (CH_3); IR (DCM): 3058, 2949, 1740, 1652, 1559, 1436, 1403, 1351, 1201, 861 and 754 cm^{-1} ; m/z (ES^+): 396 ($M^+ + 2$), 395 ($M^+ + 1$, 100).

8. Supplementary material

Crystallographic data (excluding structural factors) for the structures in this paper have been deposited at the Cambridge Crystallographic Data Centre as supplementary publication nos. CCDC 682218 (compound **14a**), CCDC 682219 (**15a**), CCDC 682220 (**16a**) and CCDC 682221 (**16b**). Copies of the data can be obtained, free of charge, on application to CCDC, 12 Union Road, Cambridge CB2 1EZ, UK (fax: +44 (0) 1223 336033 or via the web at: <http://www.ccdc.cam.ac.uk/products/csd/request/>).

Acknowledgements

We thank Leeds University for support and the Commonwealth Scholarship Commission for a studentship (to M.A.B.S.).

References and notes

- Grigg, R.; Sridharan, V. In *Advances in Cycloaddition*; Curran, D. P., Ed.; JAI: London, 1993; Vol. 3, pp 161–204.
- (a) Grigg, R.; Thornton-Pett, M.; Yoganthan, G. *Tetrahedron* **1999**, *55*, 1763–1780; (b) Grigg, R.; Hargreaves, S.; Redpath, R.; Turchi, S.; Yoganthan, G. *Synthesis* **1999**, 441–446.
- (a) Grigg, R.; Thornton-Pett, M.; Yoganthan, G. *Tetrahedron* **1999**, *55*, 8129–8140; (b) Part 63: Grigg, R.; Sarker, M. A. B. *Tetrahedron* **2006**, *62*, 10332–10343.
- Grigg, R.; Thornton-Pett, M.; Xu, J.; Xu, L.-H. *Tetrahedron* **1999**, *55*, 13841–13866.
- (a) Grigg, R.; Lansdell, M. I.; Thornton-Pett, M. *Tetrahedron* **1999**, *55*, 2025–2044; (b) Dondas, H. A.; Fishwick, C. W. G.; Grigg, R.; Kilner, C. *Tetrahedron* **2004**, *60*, 3473–3485.
- (a) Pinna, G. A.; Curzu, M. M.; Sechi, M.; Chelucci, G.; Vianello, P.; Maciocco, E. *Farmaco* **1998**, *53*, 684–689; (b) Thurkauf, A.; Hutchison, A.; Peterson, J.; Cornfield, R.; Meade, R.; Huston, K.; Harris, K.; Ross, P. C.; Gerber, K.; Ramabhadran, T. V. *J. Med. Chem.* **1995**, *38*, 2251–2255; (c) Norman, M. H.; Kelley, J. L.; Hollingsworth, E. B. *J. Med. Chem.* **1993**, *36*, 3417–3423; (d) Gentles, R. G.; Middlemiss, D.; Proctor, G. R.; Sneddon, A. H. *J. Chem. Soc., Perkin Trans. 1* **1991**, 1423–1431; (e) Berger, J. G.; Chang, W. K.; Clader, J. W.; Hou, D.; Chipkin, R. E.; McPhail, A. T. *J. Med. Chem.* **1989**, *32*, 1913–1921; (f) Crooks, P. A.; Szyndler, R.; Cox, B. *Pharm. Acta Helv.* **1980**, *55*, 134–137.
- (a) Rang, H. P.; Dale, M. M. *Pharmacology*; Churchill Livingstone: Edinburgh, 1991; (b) Albert, A. *Selective Toxicity*; Chapman and Hall: London, 1985; (c) Shorter, E. *A History of Psychiatry*; Wiley: New York, NY, 1997; (d) Song, C.; Leonard, B. E. *Fundamentals of Psychoneuroimmunology*; John Wiley and Sons: Chichester, UK, 2000.
- (a) Nyerges, M.; Bitter, I.; Kádas, I.; Tóth, G.; Tóke, L. *Tetrahedron Lett.* **1994**, *35*, 4413–4414; (b) Nyerges, M.; Bitter, I.; Kádas, I.; Tóth, G.; Tóke, L. *Tetrahedron* **1995**, *51*, 11489–11502; (c) Nyerges, M.; Rudas, M.; Bitter, I.; Tóke, L. *Tetrahedron* **1997**, *53*, 3269–3280; (d) Fejes, I.; Tóke, L.; Blaskó, G.; Nyerges, M.; Pak, C. S. *Tetrahedron* **2000**, *56*, 8545–8553.
- (a) Pak, C. S.; Nyerges, M. *Bull. Korean Chem. Soc.* **1999**, *20*, 633–635; (b) Nyerges, M.; Balázs, L.; Kádas, I.; Bitter, I.; Kövesdi, I.; Tóke, L. *Tetrahedron* **1995**, *51*, 6783–6788; (c) Poornachandran, M.; Raghunathan, R. *Tetrahedron* **2006**, *62*, 11274–11282; (d) Poornachandran, M.; Raghunathan, R. *Synth. Commun.* **2007**, *37*, 2507–2517; (e) Poornachandran, M.; Muruganathan, R.; Raghunathan, R. *Synth. Commun.* **2006**, *36*, 141–150.
- (a) Nyerges, M.; Rudas, M.; Tóth, G.; Herényi, B.; Kádas, I.; Bitter, I.; Tóke, L. *Tetrahedron* **1995**, *51*, 13321–13330; (b) Ayerbe, M.; Arrieta, A.; Cossio, F. P. *J. Org. Chem.* **1998**, *63*, 1795–1805; (c) Vivanco, S.; Lecea, B.; Arrieta, A.; Prieto, P.; Morao, I.; Linden, A.; Cossio, F. P. *J. Am. Chem. Soc.* **2000**, *122*, 6078–6092.
- (a) Grigg, R.; McMeekin, P.; Sridharan, V. *Tetrahedron* **1995**, *51*, 13331–13346.
- Yan, X.-X.; Peng, Q.; Zhang, Y.; Zhang, K.; Hong, W.; Hou, X.-L.; Wu, Y.-D. *Angew. Chem., Int. Ed.* **2006**, *45*, 1979–1983.
- Díaz-Ortiz, A.; de la Hoz, A.; Herrero, M. A.; Prieto, P.; Sánchez-Migallon, A.; Cossio, F. P.; Arrieta, A.; Vivanco, S.; Foces-Foces, C. *Mol. Divers.* **2003**, *7*, 175–180.
- (a) Kabalka, G. W.; Varma, R. S. *Org. Prep. Proced. Int.* **1987**, *19*, 283; (b) Becker, H.-D.; Sörensen, H.; Sandros, K. *J. Org. Chem.* **1986**, *51*, 3223–3226; (c) Bourguignon, J.; Le Nard, G.; Queguiner, G. *Can. J. Chem.* **1985**, *63*, 2354–2361; (d) Peterli, S.; Stumpf, R.; Schweizer, M.; Sequin, U.; Mett, H.; Traxler, P. *Helv. Chim. Acta* **1992**, *75*, 696–706; (e) Sader-Bakaoui, L.; Charton, O.; Kunesch, N.; Tilliquin, F. *Tetrahedron* **1998**, *54*, 1773–1782.
- (a) Grigg, R.; Kemp, J.; Warnock, W. J. *J. Chem. Soc., Perkin Trans. 1* **1987**, 2275–2284; (b) Amornraksa, K.; Grigg, R.; Gunaratne, H. Q. N.; Kemp, J.; Sridharan, V. *J. Chem. Soc., Perkin Trans. 1* **1987**, 2285–2296.
- Fejes, I.; Tóke, L.; Nyerges, M.; Pak, C. S. *Tetrahedron* **2000**, *56*, 639–644.
- (a) Ram, S.; Ehrenkauffer, R. E. *Tetrahedron Lett.* **1984**, *25*, 3415–3418; (b) Nielson, A. T. *J. Org. Chem.* **1962**, *27*, 1998–2001.
- Krapcho, J.; Turk, C. F.; Piala, J. J. *J. Med. Chem.* **1968**, 361–364.
- Lee, J. G.; Choi, K. I.; Koh, H. Y.; Kim, Y.; Kang, Y.; Cho, Y. S. *Synthesis* **2001**, *1*, 81–84.
- Hill, R. K.; Sawada, S.; Bock, M. G.; Greene, J. R. *Heterocycles* **1987**, *25*, 515–520; Bryce, M. R.; Gardiner, J. M.; Hursthouse, M. B.; Short, R. L. *Tetrahedron Lett.* **1987**, *28*, 577–580.